-DOCSTART- -X- -X- -X- O

A	O
27	B-Age
years	I-Age
old	I-Age
,	O
male	O
,	O
right	O
handed	O
,	O
was	O
admitted	O
for	O
a	O
2	B-Duration
years	I-Duration
history	O
of	O
very	B-Detailed_description
frequent	I-Detailed_description
gelastic	B-Disease_disorder
seizures	I-Disease_disorder
.	O

The	O
patient	O
described	O
aura	B-Sign_symptom
-	I-Sign_symptom
like	I-Sign_symptom
symptoms	I-Sign_symptom
:	O
especially	O
warmth	B-Sign_symptom
throughout	O
the	O
face	B-Biological_structure
and	O
dizziness	B-Sign_symptom
that	O
preceded	O
the	O
seizure	B-Sign_symptom
and	O
he	O
denied	O
any	O
affective	B-Sign_symptom
connotation	I-Sign_symptom
.	O

Some	B-Detailed_description
of	O
the	O
seizures	B-Sign_symptom
consisted	O
only	O
of	O
a	O
brief	B-Detailed_description
period	O
of	O
laughter	B-Sign_symptom
without	O
any	O
motor	B-Sign_symptom
involvement	I-Sign_symptom
,	O
but	O
a	O
typical	O
seizure	B-Sign_symptom
would	O
consist	O
of	O
sudden	B-Detailed_description
laughter	B-Sign_symptom
accompanied	O
by	O
simple	B-Sign_symptom
motor	I-Sign_symptom
partial	I-Sign_symptom
seizures	I-Sign_symptom
in	O
both	B-Biological_structure
arms	I-Biological_structure
,	O
more	O
often	O
being	O
involved	O
his	O
left	B-Biological_structure
arm	I-Biological_structure
,	O
without	O
impairment	B-Sign_symptom
of	I-Sign_symptom
his	I-Sign_symptom
consciousness	I-Sign_symptom
state	I-Sign_symptom
,	O
which	O
lasted	O
less	B-Detailed_description
than	I-Detailed_description
1	I-Detailed_description
minute	I-Detailed_description
.	O

He	O
had	O
no	O
previous	O
past	O
medical	O
or	O
social	O
history	O
other	O
than	O
being	O
a	O
smoker	O
:	O
10	B-Quantitative_concept
-	I-Quantitative_concept
15	I-Quantitative_concept
cigarettes	I-Quantitative_concept
per	I-Quantitative_concept
day	I-Quantitative_concept
.	O

The	O
frequency	O
of	O
the	O
seizures	B-Sign_symptom
was	O
initially	B-Detailed_description
low	B-Frequency
,	O
but	O
increased	B-Detailed_description
progressively	I-Detailed_description
over	I-Detailed_description
time	I-Detailed_description
to	O
about	O
8	B-Frequency
-	I-Frequency
10	I-Frequency
seizures	I-Frequency
/	I-Frequency
day	I-Frequency
,	O
despite	O
anti	B-Therapeutic_procedure
-	I-Therapeutic_procedure
epileptic	I-Therapeutic_procedure
treatment	I-Therapeutic_procedure
-	O
at	O
the	O
time	O
of	O
admission	O
he	O
was	O
taking	O
Keppra	B-Medication
-	O
Levetiracetam	B-Medication
3	B-Dosage
x	I-Dosage
250	I-Dosage
mg	I-Dosage
/	I-Dosage
day	I-Dosage
and	O
Phenytoin	B-Medication
3	B-Dosage
x	I-Dosage
100	I-Dosage
mg	I-Dosage
/	I-Dosage
day	I-Dosage
.	O

With	O
the	O
Neurology	B-Nonbiological_location
Electrophysiology	I-Nonbiological_location
Department	I-Nonbiological_location
assistance	O
we	O
have	O
been	O
able	O
to	O
record	O
a	O
couple	O
of	O
seizures	B-Sign_symptom
on	O
the	O
Video	B-Diagnostic_procedure
-	I-Diagnostic_procedure
EEG	I-Diagnostic_procedure
His	O
neurological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
was	O
normal	B-Lab_value
.	O

Diagnosis	O
was	O
made	O
on	O
native	B-Detailed_description
CT	B-Diagnostic_procedure
scan	I-Diagnostic_procedure
:	O
minimal	B-Detailed_description
hypodense	B-Detailed_description
frontal	B-Biological_structure
right	I-Biological_structure
paramedian	I-Biological_structure
lesion	B-Sign_symptom
(	O
Figure	O
1A	O
)	O
,	O
cerebral	B-Biological_structure
MRI	B-Diagnostic_procedure
(	O
Figure	O
1	O
B	O
-	O
F	O
)	O
showed	O
a	O
small	B-Detailed_description
right	B-Detailed_description
parenchymal	I-Detailed_description
homogeneous	B-Detailed_description
lesion	B-Sign_symptom
16	B-Volume
/	I-Volume
22	I-Volume
/	I-Volume
15	I-Volume
mm	I-Volume
,	O
well	B-Detailed_description
delimited	I-Detailed_description
,	O
involving	O
gyrus	B-Biological_structure
cinguli	I-Biological_structure
,	O
without	O
perilesional	B-Detailed_description
edema	B-Sign_symptom
and	O
mass	B-Sign_symptom
effect	I-Sign_symptom
,	O
hyperintense	B-Detailed_description
both	I-Detailed_description
on	I-Detailed_description
T1	I-Detailed_description
and	I-Detailed_description
T2	I-Detailed_description
MR	I-Detailed_description
sequences	I-Detailed_description
,	O
non	B-Detailed_description
-	I-Detailed_description
enhancing	I-Detailed_description
after	I-Detailed_description
Gadolinium	I-Detailed_description
.	O

The	O
cerebral	B-Biological_structure
lesion	B-Sign_symptom
was	O
also	O
documented	O
on	O
EEG	B-Diagnostic_procedure
and	O
video	B-Diagnostic_procedure
-	I-Diagnostic_procedure
EEG	I-Diagnostic_procedure
recordings	O
:	O
3	B-Lab_value
seizures	B-Sign_symptom
with	O
medio	B-Detailed_description
-	I-Detailed_description
frontal	I-Detailed_description
origin	I-Detailed_description
and	O
rare	B-Detailed_description
interictal	I-Detailed_description
epileptiform	I-Detailed_description
elements	I-Detailed_description
were	O
recorded	O
(	O
Figure	O
1I	O
)	O

Using	O
an	O
interhemispheric	B-Biological_structure
microsurgical	B-Therapeutic_procedure
approach	I-Therapeutic_procedure
,	O
above	B-Biological_structure
the	I-Biological_structure
corpus	I-Biological_structure
callosum	I-Biological_structure
and	O
the	O
right	B-Biological_structure
pericallosal	I-Biological_structure
artery	I-Biological_structure
,	O
at	O
the	O
level	O
of	O
gyrus	B-Biological_structure
cinguli	I-Biological_structure
,	O
a	O
yellow	B-Color
-	I-Color
gray	I-Color
,	O
infiltrative	B-Detailed_description
tumour	B-Sign_symptom
,	O
having	O
a	O
moderate	B-Severity
vascularisation	B-Detailed_description
had	O
been	O
identified	O
and	O
totally	O
removed	B-Therapeutic_procedure
.	O

The	O
anatomo	B-Diagnostic_procedure
-	I-Diagnostic_procedure
pathological	I-Diagnostic_procedure
analysis	I-Diagnostic_procedure
revealed	O
a	O
grade	B-Lab_value
Ⅱ	I-Lab_value
astrocytoma	B-Disease_disorder
.	O

The	O
patient	O
recovered	B-Sign_symptom
very	O
well	O
,	O
without	O
deficits	B-Sign_symptom
,	O
no	O
gelastic	B-Disease_disorder
seizures	I-Disease_disorder
or	O
epileptic	B-Sign_symptom
manifestations	I-Sign_symptom
;	O
three	O
months	O
after	O
operation	O
he	O
is	O
still	O
free	O
of	O
seizures	B-Sign_symptom
.	O

A	O
control	O
postop	O
CT	B-Diagnostic_procedure
revealed	O
no	O
tumor	B-Sign_symptom
(	O
1	O
G	O
,	O
H	O
)	O

-DOCSTART- -X- -X- -X- O

A	O
58	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
cotton	B-Occupation
farmer	I-Occupation
was	O
presented	O
to	O
the	O
West	B-Nonbiological_location
China	I-Nonbiological_location
Hospital	I-Nonbiological_location
of	I-Nonbiological_location
Sichuan	I-Nonbiological_location
University	I-Nonbiological_location
because	O
of	O
an	O
over	B-Duration
1	I-Duration
-	I-Duration
month	I-Duration
history	O
of	O
recurrent	B-Detailed_description
fever	B-Sign_symptom
(	O
between	B-Lab_value
38	I-Lab_value
and	I-Lab_value
40	I-Lab_value
°C	I-Lab_value
)	O
,	O
productive	B-Detailed_description
cough	B-Sign_symptom
,	O
and	O
dyspnea	B-Sign_symptom
.	O

Prior	O
to	O
admission	O
,	O
he	O
was	O
diagnosed	O
of	O
pneumonia	B-Disease_disorder
and	O
treated	O
with	O
latamoxef	B-Medication
,	O
ofloxacin	B-Medication
,	O
vancomycin	B-Medication
,	O
and	O
voriconazole	B-Medication
at	O
local	B-Nonbiological_location
hospital	I-Nonbiological_location
.	O

However	O
,	O
no	O
remission	B-Sign_symptom
of	I-Sign_symptom
symptoms	I-Sign_symptom
was	O
observed	O
.	O

Moreover	O
,	O
he	O
was	O
a	O
hepatitis	O
B	O
virus	O
carrier	O
with	O
a	O
10	O
pack	O
-	O
years	O
smoking	O
history	O
.	O

However	O
,	O
no	O
history	O
of	O
diabetes	O
mellitus	O
,	O
tuberculosis	O
,	O
and	O
use	O
of	O
glucocorticoids	O
in	O
the	O
past	O
were	O
informed	O
.	O

On	O
admission	O
,	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
,	O
145	B-Lab_value
/	I-Lab_value
95	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
;	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
,	O
120	B-Lab_value
per	I-Lab_value
minute	I-Lab_value
;	O
respiratory	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
,	O
30	B-Lab_value
per	I-Lab_value
minute	I-Lab_value
;	O
and	O
temperature	B-Diagnostic_procedure
,	O
39	B-Lab_value
.	I-Lab_value
3	I-Lab_value
°C	I-Lab_value
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
diminished	B-Sign_symptom
breath	I-Sign_symptom
sounds	I-Sign_symptom
,	O
but	O
no	O
rales	B-Sign_symptom
were	O
heard	O
,	O
and	O
evaluation	B-Diagnostic_procedure
of	I-Diagnostic_procedure
other	I-Diagnostic_procedure
systems	I-Diagnostic_procedure
was	O
unremarkable	B-Lab_value
except	O
moderate	B-Severity
edema	B-Sign_symptom
of	O
lower	B-Biological_structure
limbs	I-Biological_structure
.	O

Arterial	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
gases	I-Diagnostic_procedure
analysis	I-Diagnostic_procedure
showed	O
pH	B-Diagnostic_procedure
7	B-Lab_value
.	I-Lab_value
361	I-Lab_value
,	O
PCO2	B-Diagnostic_procedure
53	B-Lab_value
.	I-Lab_value
5	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
,	O
and	O
PO2	B-Diagnostic_procedure
62	B-Lab_value
.	I-Lab_value
8	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
.	O

Laboratory	O
data	O
(	O
Table	O
(	O
Table1	O
)	O
1	O
)	O
revealed	O
leukocytosis	B-Diagnostic_procedure
of	O
49,500	B-Lab_value
/	I-Lab_value
mm3	I-Lab_value
with	O
97	B-Lab_value
.	I-Lab_value
4	I-Lab_value
%	I-Lab_value
neutrophils	I-Lab_value
,	O
and	O
elevated	O
procalcitonin	B-Diagnostic_procedure
of	O
5	B-Lab_value
.	I-Lab_value
16	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
.	O

Chest	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
,	O
presence	O
of	O
nodules	B-Sign_symptom
,	O
masses	B-Sign_symptom
,	O
patchy	B-Sign_symptom
consolidations	I-Sign_symptom
,	O
and	O
bilateral	B-Sign_symptom
pleural	I-Sign_symptom
effusion	I-Sign_symptom
,	O
is	O
noted	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

Meanwhile	O
,	O
it	O
was	O
soon	O
alerted	O
in	O
sputum	B-Diagnostic_procedure
smear	I-Diagnostic_procedure
with	O
presence	O
of	O
filamentous	B-Detailed_description
,	O
gram	B-Detailed_description
-	I-Detailed_description
positive	I-Detailed_description
,	O
weakly	B-Detailed_description
acid	I-Detailed_description
-	I-Detailed_description
fast	I-Detailed_description
,	O
and	O
beaded	B-Detailed_description
bacilli	B-Sign_symptom
with	O
possible	O
diagnosis	O
of	O
Nocardia	B-Disease_disorder
infection	I-Disease_disorder
(	O
Fig	O
.	O
1B	O
,	O
C	O
)	O
.	O

Trimethoprim	B-Medication
-	I-Medication
sulfamethoxazole	I-Medication
(	O
3	B-Dosage
pills	I-Dosage
per	I-Dosage
6	I-Dosage
hours	I-Dosage
)	O
with	O
noninvasive	B-Detailed_description
ventilation	B-Therapeutic_procedure
was	O
promptly	O
administered	O
.	O

Sputum	B-Diagnostic_procedure
culture	I-Diagnostic_procedure
showed	O
growth	B-Lab_value
of	I-Lab_value
numerous	I-Lab_value
bacteria	I-Lab_value
that	O
were	O
precisely	O
determined	O
to	O
be	O
N	B-Sign_symptom
otitidiscaviarum	I-Sign_symptom
by	O
the	O
method	O
of	O
mass	B-Diagnostic_procedure
spectroscopy	I-Diagnostic_procedure
on	O
day	O
6	O
after	O
admission	O
(	O
Fig	O
.	O
1D	O
)	O
.	O

Antibiotics	B-Medication
were	O
thus	O
modified	O
to	O
amikacin	B-Medication
and	O
imipenem	B-Medication
in	O
addition	O
to	O
trimethoprim	B-Medication
-	I-Medication
sulfamethoxazole	I-Medication
in	O
accordance	O
with	O
the	O
sensitivity	O
test	O
.	O

However	O
,	O
the	O
patient	O
was	O
not	O
improved	B-Sign_symptom
as	O
expected	O
and	O
eventually	O
died	O
from	O
severe	B-Severity
respiratory	B-Sign_symptom
insufficiency	I-Sign_symptom
on	O
the	O
13th	O
hospital	O
day	O
.	O

-DOCSTART- -X- -X- -X- O

An	O
18	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
male	O
was	O
diagnosed	O
with	O
attention	B-Disease_disorder
-	I-Disease_disorder
deficit	I-Disease_disorder
hyperactivity	I-Disease_disorder
disorder	I-Disease_disorder
(	O
ADHD	B-Disease_disorder
)	O
in	O
2005	O
.	O

He	O
was	O
overweight	B-Sign_symptom
with	O
a	O
body	B-Diagnostic_procedure
mass	I-Diagnostic_procedure
index	I-Diagnostic_procedure
(	O
BMI	B-Diagnostic_procedure
)	O
of	O
40	B-Lab_value
.	O

He	O
was	O
started	O
on	O
quetiapine	B-Medication
fumarate	I-Medication
(	B-Medication
Seroquel	I-Medication
®	I-Medication
)	I-Medication
900	B-Dosage
mg	I-Dosage
daily	I-Dosage
in	O
April	O
2005	O
and	O
methylphenidate	B-Medication
(	B-Medication
Concerta	I-Medication
®	I-Medication
)	I-Medication
54	B-Dosage
mg	I-Dosage
daily	I-Dosage
in	O
September	O
2005	O
.	O

In	O
the	O
beginning	O
of	O
August	O
2006	O
he	O
was	O
admitted	O
to	O
his	O
local	B-Nonbiological_location
hospital	I-Nonbiological_location
with	O
severe	B-Severity
dyspnoea	B-Sign_symptom
,	O
tachypnea	B-Sign_symptom
,	O
tachycardia	B-Sign_symptom
,	O
and	O
cyanosis	B-Sign_symptom
.	O

On	O
admission	O
the	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
120	B-Lab_value
/	I-Lab_value
80	I-Lab_value
mmHg	I-Lab_value
,	O
and	O
the	O
arterial	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
gas	I-Diagnostic_procedure
revealed	O
a	O
pH	B-Diagnostic_procedure
of	O
7	B-Lab_value
.	I-Lab_value
45	I-Lab_value
,	O
pCO2	B-Diagnostic_procedure
of	O
3	B-Lab_value
.	I-Lab_value
55	I-Lab_value
kPa	I-Lab_value
,	O
paO2	B-Diagnostic_procedure
of	O
7	B-Lab_value
.	I-Lab_value
76	I-Lab_value
kPa	I-Lab_value
,	O
and	O
BE	B-Diagnostic_procedure
of	O
−	B-Lab_value
5	I-Lab_value
.	I-Lab_value
1	I-Lab_value
mmol	I-Lab_value
/	I-Lab_value
l	I-Lab_value
.	O

C	B-Diagnostic_procedure
-	I-Diagnostic_procedure
reactive	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
was	O
not	B-Lab_value
elevated	I-Lab_value
.	O

The	O
chest	B-Biological_structure
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
showed	O
an	O
enlarged	B-Sign_symptom
heart	I-Sign_symptom
.	O

He	O
developed	O
hemoptysis	B-Sign_symptom
and	O
was	O
treated	O
with	O
unfractionated	B-Detailed_description
heparin	B-Medication
in	O
suspicion	O
of	O
pulmonary	B-Biological_structure
embolism	B-Sign_symptom
.	O

He	O
subsequently	O
developed	O
cardiogenic	B-Disease_disorder
shock	I-Disease_disorder
and	O
was	O
treated	O
with	O
vasoactive	B-Medication
drugs	I-Medication
.	O

In	O
spite	O
of	O
the	O
treatment	O
he	O
became	O
oliguric	B-Sign_symptom
and	O
his	O
liver	B-Diagnostic_procedure
enzymes	I-Diagnostic_procedure
were	O
rising	B-Lab_value
.	O

He	O
was	O
referred	O
to	O
our	O
hospital	B-Nonbiological_location
for	O
further	O
treatment	O
.	O

On	O
admission	O
the	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
90	B-Lab_value
/	I-Lab_value
60	I-Lab_value
mmHg	I-Lab_value
,	O
despite	O
infusion	O
with	O
noradrenaline	B-Medication
.	O

His	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
was	O
130	B-Lab_value
/	I-Lab_value
minute	I-Lab_value
and	O
his	O
temperature	B-Diagnostic_procedure
was	O
38	B-Lab_value
.	I-Lab_value
4	I-Lab_value
°C	I-Lab_value
.	O

A	O
thoracic	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
scan	I-Diagnostic_procedure
did	B-Sign_symptom
not	I-Sign_symptom
show	I-Sign_symptom
pulmonary	I-Sign_symptom
embolism	I-Sign_symptom
.	O

Echocardiography	B-Diagnostic_procedure
revealed	O
biventricular	B-Sign_symptom
failure	I-Sign_symptom
and	O
left	B-Diagnostic_procedure
ventricular	I-Diagnostic_procedure
end	I-Diagnostic_procedure
diastolic	I-Diagnostic_procedure
diameter	I-Diagnostic_procedure
was	O
7	B-Distance
cm	I-Distance
.	O

The	O
left	B-Biological_structure
ventricle	I-Biological_structure
was	O
severely	B-Severity
hypokinetic	B-Lab_value
with	O
an	O
ejection	B-Diagnostic_procedure
fraction	I-Diagnostic_procedure
(	O
EF	B-Diagnostic_procedure
)	O
of	O
20	B-Lab_value
%	I-Lab_value
-	I-Lab_value
25	I-Lab_value
%	I-Lab_value
.	O

The	O
left	B-Diagnostic_procedure
ventricular	I-Diagnostic_procedure
end	I-Diagnostic_procedure
diastolic	I-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
markedly	O
elevated	B-Lab_value
,	O
and	O
there	O
was	O
a	O
moderate	B-Lab_value
mitral	B-Sign_symptom
regurgitation	I-Sign_symptom
.	O

Intermittent	B-Detailed_description
hemodialysis	B-Therapeutic_procedure
was	O
initiated	O
.	O

His	O
liver	B-Diagnostic_procedure
function	I-Diagnostic_procedure
improved	B-Lab_value
slightly	B-Severity
,	O
but	O
despite	O
dialysis	O
the	O
renal	B-Diagnostic_procedure
function	I-Diagnostic_procedure
deteriorated	B-Lab_value
with	O
increasing	B-Lab_value
creatinine	B-Diagnostic_procedure
values	I-Diagnostic_procedure
.	O

After	O
three	O
days	O
there	O
was	O
a	O
further	O
worsening	B-Lab_value
of	O
the	O
left	B-Diagnostic_procedure
ventricular	I-Diagnostic_procedure
systolic	I-Diagnostic_procedure
function	I-Diagnostic_procedure
with	O
an	O
ejection	B-Diagnostic_procedure
fraction	I-Diagnostic_procedure
of	O
10	B-Lab_value
%	I-Lab_value
-	I-Lab_value
12	I-Lab_value
%	I-Lab_value
and	O
marked	O
pulmonary	B-Sign_symptom
hypertension	I-Sign_symptom
with	O
systolic	B-Diagnostic_procedure
pulmonary	I-Diagnostic_procedure
pressure	I-Diagnostic_procedure
estimated	O
to	O
30	B-Lab_value
mmHg	I-Lab_value
.	O

The	O
clinical	O
picture	O
resembled	O
dilated	B-Detailed_description
cardiomyopathy	B-Disease_disorder
with	O
low	B-Sign_symptom
output	I-Sign_symptom
failure	I-Sign_symptom
causing	O
renal	B-Biological_structure
and	O
liver	B-Biological_structure
failure	B-Sign_symptom
.	O

We	O
suspected	O
drug	B-Detailed_description
-	I-Detailed_description
induced	I-Detailed_description
cardiomyopathy	O
and	O
methylphenidate	B-Medication
and	O
quetiapine	B-Medication
fumarate	I-Medication
were	O
discontinued	O
.	O

Screening	B-Diagnostic_procedure
for	I-Diagnostic_procedure
infectious	I-Diagnostic_procedure
pathogens	I-Diagnostic_procedure
,	O
immunological	B-Diagnostic_procedure
markers	I-Diagnostic_procedure
,	O
and	O
iron	B-Diagnostic_procedure
or	O
amyloid	B-Diagnostic_procedure
deposition	I-Diagnostic_procedure
were	O
all	O
negative	B-Lab_value
.	O

After	O
three	O
days	O
he	O
was	O
transferred	O
to	O
the	O
National	B-Nonbiological_location
Hospital	I-Nonbiological_location
(	I-Nonbiological_location
Rikshospitalet	I-Nonbiological_location
,	I-Nonbiological_location
Oslo	I-Nonbiological_location
)	I-Nonbiological_location
with	O
ongoing	O
noradrenaline	B-Medication
and	O
dobutamine	B-Medication
infusions	O
.	O

Shortly	O
after	O
admission	O
an	O
intraaortic	B-Therapeutic_procedure
balloon	I-Therapeutic_procedure
pump	I-Therapeutic_procedure
(	O
IABP	B-Therapeutic_procedure
)	O
was	O
inserted	O
and	O
noradrenaline	O
was	O
replaced	O
by	O
nitroprusside	B-Medication
.	O

Coronary	B-Diagnostic_procedure
angiography	I-Diagnostic_procedure
was	O
normal	B-Lab_value
.	O

Endomyocardial	B-Biological_structure
biopsy	B-Diagnostic_procedure
from	O
the	O
right	B-Biological_structure
ventricle	I-Biological_structure
did	O
not	O
reveal	O
any	O
distinct	O
myocardial	B-Disease_disorder
pathology	I-Disease_disorder
.	O

On	O
treatment	O
with	O
IABP	O
,	O
nitroprusside	O
,	O
and	O
dialysis	B-Therapeutic_procedure
,	O
the	O
clinical	B-Diagnostic_procedure
situation	I-Diagnostic_procedure
gradually	O
improved	B-Lab_value
and	O
the	O
liver	B-Diagnostic_procedure
function	I-Diagnostic_procedure
returned	O
to	O
normal	B-Lab_value
.	O

His	O
renal	B-Diagnostic_procedure
function	I-Diagnostic_procedure
also	O
improved	B-Lab_value
with	O
increasing	O
diuresis	B-Sign_symptom
and	O
creatinine	B-Diagnostic_procedure
fell	O
from	O
798	B-Lab_value
to	O
98	B-Lab_value
μmol	I-Lab_value
/	I-Lab_value
l	I-Lab_value
.	O

His	O
EF	B-Diagnostic_procedure
was	O
still	O
markedly	O
reduced	B-Lab_value
(	O
15	B-Lab_value
%	I-Lab_value
)	O
.	O

Because	O
of	O
behavioral	B-Sign_symptom
problems	I-Sign_symptom
and	O
adipose	B-Sign_symptom
stature	I-Sign_symptom
,	O
he	O
was	O
denied	O
a	O
heart	B-Therapeutic_procedure
transplant	I-Therapeutic_procedure
.	O

He	O
was	O
treated	O
with	O
IABP	O
for	O
26	B-Duration
days	I-Duration
,	O
and	O
after	B-Duration
28	I-Duration
days	I-Duration
he	O
was	O
transferred	O
back	O
to	O
our	B-Nonbiological_location
hospital	I-Nonbiological_location
.	O

At	O
that	O
time	O
his	O
liver	B-Diagnostic_procedure
and	I-Diagnostic_procedure
renal	I-Diagnostic_procedure
functions	I-Diagnostic_procedure
were	O
normal	B-Lab_value
.	O

He	O
was	O
treated	O
with	O
an	O
angiotensin	B-Medication
-	I-Medication
converting	I-Medication
enzyme	I-Medication
(	I-Medication
ACE	I-Medication
)	I-Medication
-	I-Medication
inhibitor	I-Medication
,	O
a	O
beta	B-Medication
-	I-Medication
blocker	I-Medication
,	O
and	O
diuretics	B-Medication
.	O

During	O
the	O
following	O
two	B-Duration
weeks	I-Duration
his	O
clinical	B-Diagnostic_procedure
status	I-Diagnostic_procedure
improved	B-Lab_value
and	O
he	O
was	O
subsequently	O
discharged	O
to	O
his	B-Nonbiological_location
home	I-Nonbiological_location
.	O

The	O
echocardiography	B-Diagnostic_procedure
still	O
showed	O
markedly	O
dilated	B-Lab_value
left	B-Biological_structure
ventricle	I-Biological_structure
with	O
EF	B-Diagnostic_procedure
of	O
20	B-Lab_value
%	I-Lab_value
.	O

In	O
March	O
2007	O
,	O
his	O
clinical	B-Diagnostic_procedure
status	I-Diagnostic_procedure
was	O
improved	B-Lab_value
and	O
he	O
was	O
in	O
function	B-Diagnostic_procedure
class	I-Diagnostic_procedure
II	B-Lab_value
(	O
New	B-Detailed_description
York	I-Detailed_description
Heart	I-Detailed_description
Association	I-Detailed_description
)	O
with	O
an	O
EF	B-Diagnostic_procedure
estimated	O
by	O
echocardiography	B-Diagnostic_procedure
to	O
30	B-Lab_value
%	I-Lab_value
-	I-Lab_value
35	I-Lab_value
%	I-Lab_value
.	O

-DOCSTART- -X- -X- -X- O

A	O
25	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
female	O
patient	O
had	O
noticed	O
left	B-Detailed_description
-	I-Detailed_description
sided	I-Detailed_description
visual	B-Disease_disorder
loss	I-Disease_disorder
and	O
amenorrhea	B-Disease_disorder
2	O
years	O
prior	O
to	O
being	O
seen	O
,	O
with	O
right	B-Detailed_description
hemiparesis	B-Disease_disorder
developing	O
6	O
months	O
beforehand	O
.	O

Aggravated	B-Severity
symptoms	B-Sign_symptom
(	O
drooping	B-Sign_symptom
at	O
corner	B-Biological_structure
of	I-Biological_structure
right	I-Biological_structure
lip	I-Biological_structure
and	O
bilateral	B-Detailed_description
temporal	B-Detailed_description
hemianopia	B-Disease_disorder
)	O
finally	O
prompted	O
hospitalization	O
.	O

At	O
that	O
time	O
,	O
a	O
massive	B-Severity
(	O
>	B-Distance
5	I-Distance
cm	I-Distance
)	O
tumor	B-Sign_symptom
of	O
intra	B-Biological_structure
-	I-Biological_structure
and	I-Biological_structure
suprasellar	I-Biological_structure
location	I-Biological_structure
,	O
excluding	B-Detailed_description
mesencephalon	I-Detailed_description
backward	I-Detailed_description
,	O
was	O
seen	O
on	O
computerized	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
of	O
the	O
head	B-Biological_structure
(	O
Fig	O
.	O
1a	O
)	O
.	O

Further	O
testing	O
revealed	O
an	O
exceedingly	B-Lab_value
high	I-Lab_value
-	O
serum	B-Biological_structure
level	O
of	O
prolactin	B-Diagnostic_procedure
(	O
PRL	B-Diagnostic_procedure
)	O
(	O
4408	B-Lab_value
ng	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
)	O
,	O
whereas	O
levels	O
of	O
all	O
other	B-Diagnostic_procedure
pituitary	I-Diagnostic_procedure
hormones	I-Diagnostic_procedure
were	O
within	B-Lab_value
reference	I-Lab_value
ranges	I-Lab_value
(	B-Diagnostic_procedure
growth	I-Diagnostic_procedure
hormone	I-Diagnostic_procedure
(	O
GH	B-Diagnostic_procedure
)	O
,	O
0	B-Lab_value
.	I-Lab_value
50	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
;	O
luteinizing	B-Diagnostic_procedure
hormone	I-Diagnostic_procedure
(	O
LH	B-Diagnostic_procedure
)	O
,	O
2	B-Lab_value
.	I-Lab_value
60	I-Lab_value
mIU	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
;	O
follicle	B-Diagnostic_procedure
-	I-Diagnostic_procedure
stimulating	I-Diagnostic_procedure
hormone	I-Diagnostic_procedure
(	O
FSH	B-Diagnostic_procedure
)	O
,	O
4	B-Lab_value
.	I-Lab_value
57	I-Lab_value
mIU	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
;	O
adrenocorticotropic	B-Diagnostic_procedure
hormone	I-Diagnostic_procedure
(	O
ACTH	B-Diagnostic_procedure
)	O
,	O
37	B-Lab_value
.	I-Lab_value
4	I-Lab_value
pg	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
;	O
thyroid	B-Diagnostic_procedure
-	I-Diagnostic_procedure
stimulating	I-Diagnostic_procedure
hormone	I-Diagnostic_procedure
(	O
TSH	B-Diagnostic_procedure
)	O
,	O
2	B-Lab_value
.	I-Lab_value
68	I-Lab_value
μIU	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
)	O
.	O

T1	B-Detailed_description
-	I-Detailed_description
weighted	I-Detailed_description
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
(	O
MR	B-Diagnostic_procedure
)	O
imaging	O
with	O
contrast	B-Detailed_description
(	O
gadolinium	B-Detailed_description
)	O
showed	O
homogeneous	B-Detailed_description
tumor	B-Sign_symptom
enhancement	B-Detailed_description
,	O
but	O
adjacent	B-Biological_structure
tissue	I-Biological_structure
was	O
not	O
edematous	B-Sign_symptom
in	O
T2	B-Diagnostic_procedure
-	I-Diagnostic_procedure
weighted	I-Diagnostic_procedure
views	I-Diagnostic_procedure
.	O

The	O
mass	B-Sign_symptom
did	O
not	O
regress	B-Sign_symptom
,	O
despite	O
a	O
4	B-Duration
-	I-Duration
week	I-Duration
course	O
of	O
the	O
dopamine	B-Medication
analog	I-Medication
,	O
cabergoline	B-Medication
(	O
1	B-Dosage
mg	I-Dosage
/	I-Dosage
week	I-Dosage
)	O
,	O
and	O
serum	B-Biological_structure
PRL	B-Diagnostic_procedure
level	O
(	O
2207	B-Lab_value
ng	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
)	O
remained	O
elevated	B-Lab_value
.	O

Relative	O
to	O
status	O
at	O
admission	O
,	O
the	O
right	B-Biological_structure
lateral	I-Biological_structure
ventricle	I-Biological_structure
also	O
had	O
enlarged	B-Sign_symptom
somewhat	B-Severity
,	O
due	O
to	O
obstruction	B-Sign_symptom
at	O
foramen	B-Biological_structure
of	I-Biological_structure
Monro	I-Biological_structure
(	O
Fig	O
.	O
1b	O
)	O
.	O

In	O
light	O
of	O
this	O
intransigence	O
,	O
surgical	B-Detailed_description
debulking	B-Therapeutic_procedure
of	O
tumor	O
was	O
elected	O
first	O
,	O
through	O
craniotomy	B-Therapeutic_procedure
and	O
then	O
via	O
transsphenoidal	B-Therapeutic_procedure
approach	I-Therapeutic_procedure
.	O

The	O
hardened	B-Texture
elastic	I-Texture
quality	O
of	O
the	O
tumor	B-Sign_symptom
and	O
its	O
strong	B-Severity
attachments	B-Sign_symptom
to	O
neighboring	B-Biological_structure
structures	I-Biological_structure
prevented	O
complete	B-Therapeutic_procedure
removal	I-Therapeutic_procedure
,	O
but	O
related	O
mass	B-Sign_symptom
effect	I-Sign_symptom
was	O
significantly	O
reduced	O
and	O
serum	B-Biological_structure
PRL	B-Diagnostic_procedure
level	O
declined	B-Lab_value
(	O
to	O
250	B-Lab_value
ng	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
)	O
in	O
steps	O
at	O
each	O
procedural	O
stage	O
.	O

But	O
the	O
normalization	B-Lab_value
of	O
PRL	B-Diagnostic_procedure
level	O
had	O
not	O
been	O
achieved	O
with	O
the	O
administration	O
of	O
cabergoline	B-Medication
increased	O
up	O
to	O
0	B-Dosage
.	I-Dosage
5	I-Dosage
mg	I-Dosage
/	I-Dosage
day	I-Dosage
.	O

The	O
residual	O
tumor	O
showed	O
no	O
evidence	O
of	O
regrowth	B-Sign_symptom
or	O
distant	B-Detailed_description
metastasis	B-Sign_symptom
1	O
year	O
after	O
surgery	O
.	O

Histopathologically	B-Diagnostic_procedure
,	O
hematoxylin	B-Diagnostic_procedure
and	I-Diagnostic_procedure
eosin	I-Diagnostic_procedure
(	O
H&E	B-Diagnostic_procedure
)	O
-	O
stained	O
sections	O
of	O
specimens	B-Biological_structure
from	O
the	O
first	O
and	O
second	O
surgical	O
procedures	O
similarly	O
were	O
composed	O
of	O
polygonal	B-Detailed_description
and	O
spindle	B-Sign_symptom
cells	I-Sign_symptom
with	O
round	B-Shape
,	O
oval	B-Shape
,	O
or	O
elongated	B-Shape
nuclei	B-Diagnostic_procedure
and	O
eosinophilic	B-Lab_value
cytoplasm	B-Diagnostic_procedure
(	O
Fig	O
.	O
2a	O
-	O
c	O
)	O
.	O

The	O
cells	O
formed	O
irregular	B-Detailed_description
nests	I-Detailed_description
or	O
short	B-Detailed_description
fascicles	I-Detailed_description
,	O
accompanied	O
by	O
frequent	B-Detailed_description
hyaline	I-Detailed_description
changes	I-Detailed_description
in	I-Detailed_description
vessel	I-Detailed_description
walls	I-Detailed_description
and	I-Detailed_description
vacuolation	I-Detailed_description
(	O
Fig	O
.	O
2d	O
)	O
.	O

Some	O
nuclear	B-Sign_symptom
pleomorphism	I-Sign_symptom
was	O
prominent	O
;	O
on	O
the	O
other	O
hand	O
,	O
neither	O
a	O
high	B-Sign_symptom
mitotic	I-Sign_symptom
rate	I-Sign_symptom
nor	O
necrosis	B-Sign_symptom
was	O
evident	O
(	O
Fig	O
.	O
2b	O
,	O
c	O
)	O
.	O

Conspicuous	O
fibrous	B-Sign_symptom
change	I-Sign_symptom
of	O
tumor	B-Biological_structure
stroma	I-Biological_structure
was	O
noted	O
focally	O
as	O
well	O
(	O
Fig	O
.	O
3a	O
)	O
.	O

The	O
chromophobic	B-Lab_value
nature	O
of	O
tumor	B-Biological_structure
cells	I-Biological_structure
was	O
confirmed	O
by	O
Pearse	B-Diagnostic_procedure
`	I-Diagnostic_procedure
s	I-Diagnostic_procedure
Periodic	I-Diagnostic_procedure
Acid	I-Diagnostic_procedure
Schiff	I-Diagnostic_procedure
(	O
PAS	B-Diagnostic_procedure
)	O
stain	O
(	O
Fig	O
.	O
3b	O
)	O
.	O

Immunostains	B-Diagnostic_procedure
showed	O
strong	O
diffuse	O
positivity	B-Lab_value
for	O
PRL	B-Diagnostic_procedure
(	O
Fig	O
.	O
3c	O
)	O
,	O
chromogranin	B-Diagnostic_procedure
-	I-Diagnostic_procedure
A	I-Diagnostic_procedure
,	O
and	O
synaptophysin	B-Diagnostic_procedure
.	O

No	B-Lab_value
other	B-Diagnostic_procedure
hormones	I-Diagnostic_procedure
(	O
GH	B-Diagnostic_procedure
,	O
TSH	B-Diagnostic_procedure
,	O
ACTH	B-Diagnostic_procedure
,	O
LH	B-Diagnostic_procedure
,	O
FSH	B-Diagnostic_procedure
)	O
were	O
expressed	O
by	O
tumor	O
cells	O
,	O
and	O
the	O
other	B-Diagnostic_procedure
markers	I-Diagnostic_procedure
,	O
including	O
S	B-Diagnostic_procedure
-	I-Diagnostic_procedure
100	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
(	O
Fig	O
.	O
3d	O
)	O
,	O
glial	B-Diagnostic_procedure
fibrillary	I-Diagnostic_procedure
acidic	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
(	O
GFAP	B-Diagnostic_procedure
)	O
,	O
epithelial	B-Diagnostic_procedure
membrane	I-Diagnostic_procedure
antigen	I-Diagnostic_procedure
(	O
EMA	B-Diagnostic_procedure
)	O
,	O
cytokeratin	B-Diagnostic_procedure
AE1	I-Diagnostic_procedure
/	I-Diagnostic_procedure
AE3	I-Diagnostic_procedure
(	O
CK	B-Diagnostic_procedure
AE1	I-Diagnostic_procedure
/	I-Diagnostic_procedure
AE3	I-Diagnostic_procedure
)	O
,	O
vimentin	B-Diagnostic_procedure
,	O
p53	B-Diagnostic_procedure
,	O
and	O
bcl	B-Diagnostic_procedure
-	I-Diagnostic_procedure
2	I-Diagnostic_procedure
,	O
were	O
also	O
negative	B-Lab_value
by	O
immunostaining	O
.	O

Ki	B-Diagnostic_procedure
-	I-Diagnostic_procedure
67	I-Diagnostic_procedure
labeling	I-Diagnostic_procedure
index	I-Diagnostic_procedure
was	O
approximately	O
2	B-Lab_value
%	I-Lab_value
.	O

A	O
final	O
diagnosis	O
of	O
PRL	B-Detailed_description
-	I-Detailed_description
producing	I-Detailed_description
pituitary	B-Disease_disorder
adenoma	I-Disease_disorder
was	O
reached	O
after	O
considering	O
the	O
immunohistochemical	O
profile	O
,	O
suprasellar	O
location	O
,	O
and	O
prolactin	O
production	O
of	O
the	O
tumor	O
,	O
as	O
well	O
as	O
the	O
absence	O
of	O
metastatic	O
foci	O
and	O
invasion	O
into	O
surrounding	O
tissue	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
74	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
was	O
referred	O
to	O
our	O
hospital	B-Nonbiological_location
in	O
November	O
2000	O
because	O
of	O
liver	B-Sign_symptom
dysfunction	I-Sign_symptom
detected	O
during	O
a	O
medical	O
checkup	O
.	O

The	O
patient	O
had	O
been	O
diagnosed	O
with	O
nephrotic	B-Disease_disorder
syndrome	I-Disease_disorder
in	O
1995	O
.	O

Laboratory	B-Diagnostic_procedure
examinations	I-Diagnostic_procedure
showed	O
elevated	B-Lab_value
serum	B-Diagnostic_procedure
hepatobiliary	I-Diagnostic_procedure
enzymes	I-Diagnostic_procedure
and	O
IgM	B-Diagnostic_procedure
,	O
and	O
the	O
presence	B-Lab_value
of	O
antimitochondrial	B-Diagnostic_procedure
antibodies	I-Diagnostic_procedure
.	O

Serologic	B-Diagnostic_procedure
markers	I-Diagnostic_procedure
for	O
Hepatitis	B-Diagnostic_procedure
B	I-Diagnostic_procedure
and	I-Diagnostic_procedure
C	I-Diagnostic_procedure
viruses	O
were	O
negative	B-Lab_value
.	O

Histopathologic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
a	O
liver	B-Biological_structure
biopsy	B-Diagnostic_procedure
specimen	I-Diagnostic_procedure
obtained	O
at	O
laparoscopy	B-Therapeutic_procedure
revealed	O
non	B-Detailed_description
-	I-Detailed_description
suppurative	I-Detailed_description
destructive	B-Detailed_description
cholangitis	B-Disease_disorder
in	O
the	O
portal	B-Biological_structure
area	I-Biological_structure
(	O
Figure	O
1	O
)	O
.	O

The	O
diagnosis	O
of	O
PBC	B-Disease_disorder
(	O
Scheuer	B-Disease_disorder
stage	I-Disease_disorder
3	I-Disease_disorder
)	O
was	O
confirmed	O
and	O
ursodeoxycholic	B-Medication
acid	I-Medication
,	O
900	B-Dosage
mg	I-Dosage
daily	B-Frequency
,	O
was	O
started	O
.	O

In	O
January	O
and	O
June	O
2002	O
,	O
the	O
patient	O
underwent	O
endoscopic	B-Therapeutic_procedure
variceal	I-Therapeutic_procedure
ligation	I-Therapeutic_procedure
plus	O
endoscopic	B-Therapeutic_procedure
injection	I-Therapeutic_procedure
sclerotherapy	I-Therapeutic_procedure
as	O
well	O
as	O
argon	B-Therapeutic_procedure
plasma	I-Therapeutic_procedure
coagulation	I-Therapeutic_procedure
for	O
worsening	B-Severity
esophageal	B-Sign_symptom
varices	I-Sign_symptom
.	O

In	O
September	O
2007	O
,	O
the	O
patient	O
was	O
admitted	O
for	O
the	O
treatment	O
of	O
recurrent	B-Severity
esophageal	B-Sign_symptom
varices	I-Sign_symptom
.	O

The	O
platelet	B-Diagnostic_procedure
count	I-Diagnostic_procedure
had	O
ranged	O
between	O
52	B-Lab_value
×	I-Lab_value
109	I-Lab_value
/	I-Lab_value
L	I-Lab_value
and	O
69	B-Lab_value
×	I-Lab_value
109	I-Lab_value
/	I-Lab_value
L	I-Lab_value
for	O
several	B-Duration
years	I-Duration
,	O
but	O
it	O
was	O
noted	O
to	O
decrease	B-Lab_value
from	O
61	B-Lab_value
×	I-Lab_value
109	I-Lab_value
/	I-Lab_value
L	I-Lab_value
in	O
June	O
2007	O
to	O
8	B-Lab_value
×	I-Lab_value
109	I-Lab_value
/	I-Lab_value
L	I-Lab_value
just	O
before	O
admission	O
.	O

Before	O
the	O
deterioration	B-Detailed_description
of	O
thrombocytopenia	B-Sign_symptom
,	O
the	O
patient	O
had	O
no	O
infectious	B-Disease_disorder
diseases	I-Disease_disorder
and	O
received	O
no	O
other	O
medication	B-Medication
.	O

On	O
admission	O
,	O
the	O
patient	O
had	O
neither	O
purpura	B-Sign_symptom
nor	O
bleeding	B-Sign_symptom
episodes	I-Sign_symptom
.	O

Table	O
1	O
shows	O
the	O
laboratory	O
data	O
on	O
admission	O
.	O

The	O
platelet	B-Diagnostic_procedure
-	I-Diagnostic_procedure
associated	I-Diagnostic_procedure
IgG	I-Diagnostic_procedure
level	I-Diagnostic_procedure
was	O
markedly	B-Detailed_description
high	B-Lab_value
.	O

Bone	B-Biological_structure
marrow	I-Biological_structure
biopsy	B-Diagnostic_procedure
revealed	O
normocellular	B-Sign_symptom
marrow	I-Sign_symptom
without	O
cellular	B-Sign_symptom
atypia	I-Sign_symptom
.	O

Ultrasonography	B-Diagnostic_procedure
and	O
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
revealed	O
a	O
cirrhotic	B-Sign_symptom
liver	B-Biological_structure
with	O
splenomegaly	B-Sign_symptom
,	O
ascites	B-Sign_symptom
,	O
and	O
gallstones	B-Sign_symptom
.	O

The	O
spleen	B-Diagnostic_procedure
size	I-Diagnostic_procedure
had	O
remained	O
unchanged	B-Lab_value
from	O
previous	B-Detailed_description
imaging	B-Diagnostic_procedure
examinations	I-Diagnostic_procedure
.	O

Based	O
on	O
these	O
findings	O
,	O
the	O
association	O
of	O
PBC	B-Disease_disorder
(	O
decompensated	B-Disease_disorder
liver	I-Disease_disorder
cirrhosis	I-Disease_disorder
)	O
with	O
ITP	B-Disease_disorder
was	O
diagnosed	O
.	O

Human	B-Diagnostic_procedure
leukocyte	I-Diagnostic_procedure
antigen	I-Diagnostic_procedure
(	I-Diagnostic_procedure
HLA	I-Diagnostic_procedure
)	I-Diagnostic_procedure
genotyping	I-Diagnostic_procedure
determined	O
by	O
polymerase	B-Diagnostic_procedure
chain	I-Diagnostic_procedure
reaction	I-Diagnostic_procedure
-	I-Diagnostic_procedure
sequencing	I-Diagnostic_procedure
-	I-Diagnostic_procedure
based	I-Diagnostic_procedure
typing	I-Diagnostic_procedure
or	O
polymerase	B-Diagnostic_procedure
chain	I-Diagnostic_procedure
reaction	I-Diagnostic_procedure
-	I-Diagnostic_procedure
sequence	I-Diagnostic_procedure
specific	I-Diagnostic_procedure
primers	I-Diagnostic_procedure
(	O
SRL	O
,	O
Inc	O
.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
detected	O
A	B-Sign_symptom
*	I-Sign_symptom
02010101	I-Sign_symptom
,	O
B	B-Sign_symptom
*	I-Sign_symptom
400201	I-Sign_symptom
,	O
C	B-Sign_symptom
*	I-Sign_symptom
030401	I-Sign_symptom
,	O
C	B-Sign_symptom
*	I-Sign_symptom
07020101	I-Sign_symptom
,	O
DPB1	B-Sign_symptom
*	I-Sign_symptom
0501	I-Sign_symptom
,	O
DQA1	B-Sign_symptom
*	I-Sign_symptom
0103	I-Sign_symptom
,	O
DQA1	B-Sign_symptom
*	I-Sign_symptom
030101	I-Sign_symptom
,	O
DQB1	B-Sign_symptom
*	I-Sign_symptom
030201	I-Sign_symptom
,	O
DQB1	B-Sign_symptom
*	I-Sign_symptom
060101	I-Sign_symptom
,	O
DRB1	B-Sign_symptom
*	I-Sign_symptom
080201	I-Sign_symptom
,	O
and	O
DRB1	B-Sign_symptom
*	I-Sign_symptom
080302	I-Sign_symptom
.	O

The	O
13C	B-Diagnostic_procedure
urea	I-Diagnostic_procedure
breath	I-Diagnostic_procedure
test	I-Diagnostic_procedure
for	O
H	B-Diagnostic_procedure
pylori	I-Diagnostic_procedure
infection	I-Diagnostic_procedure
was	O
negative	B-Lab_value
.	O

Figure	O
2	O
shows	O
the	O
clinical	O
course	O
.	O

Oral	O
prednisolone	B-Medication
,	O
30	B-Dosage
mg	I-Dosage
daily	B-Frequency
,	O
for	O
ITP	O
was	O
started	O
on	O
day	O
11	O
,	O
and	O
diuretic	B-Medication
therapy	I-Medication
combined	O
with	O
albumin	B-Medication
infusion	I-Medication
for	O
ascites	B-Sign_symptom
was	O
performed	O
.	O

As	O
the	O
platelet	B-Diagnostic_procedure
count	I-Diagnostic_procedure
did	B-Lab_value
not	I-Lab_value
increase	I-Lab_value
notably	I-Lab_value
,	O
pulse	B-Medication
therapy	I-Medication
with	O
intravenous	O
methylprednisolone	B-Medication
,	O
1	B-Dosage
g	I-Dosage
daily	B-Frequency
,	O
was	O
added	O
on	O
d	B-Duration
22	I-Duration
to	I-Duration
24	I-Duration
.	O

However	O
,	O
the	O
response	O
was	O
weak	B-Lab_value
and	O
temporary	B-Detailed_description
.	O

On	O
d	O
31	O
,	O
mild	B-Severity
melena	B-Sign_symptom
was	O
identified	O
.	O

The	O
patient	O
was	O
given	O
a	O
trial	B-Detailed_description
of	O
intravenous	O
immune	B-Medication
gamma	I-Medication
globulin	I-Medication
therapy	I-Medication
,	O
25	B-Dosage
g	I-Dosage
daily	B-Frequency
,	O
on	O
d	B-Duration
32	I-Duration
to	I-Duration
36	I-Duration
,	O
combined	O
with	O
a	O
second	B-Detailed_description
round	I-Detailed_description
of	O
intravenous	O
methylprednisolone	B-Medication
pulse	I-Medication
therapy	I-Medication
on	O
d	B-Duration
32	I-Duration
to	I-Duration
34	I-Duration
.	O

Because	O
a	O
moderate	B-Lab_value
response	O
was	O
observed	O
,	O
prednisolone	B-Medication
was	O
continued	O
,	O
and	O
the	O
platelet	B-Diagnostic_procedure
count	I-Diagnostic_procedure
increased	B-Lab_value
slowly	I-Lab_value
.	O

The	O
ascites	B-Sign_symptom
was	I-Sign_symptom
relatively	I-Sign_symptom
well	I-Sign_symptom
controlled	I-Sign_symptom
with	O
diuretics	B-Medication
at	O
discharge	O
.	O

Considering	O
the	O
decompensated	B-Disease_disorder
liver	I-Disease_disorder
cirrhosis	I-Disease_disorder
and	O
the	O
platelet	B-Diagnostic_procedure
count	I-Diagnostic_procedure
,	O
we	O
determined	O
the	O
patient	O
required	O
careful	O
follow	O
-	O
up	O
of	O
esophageal	B-Sign_symptom
varices	I-Sign_symptom
without	O
prophylactic	B-Therapeutic_procedure
endoscopic	I-Therapeutic_procedure
therapy	I-Therapeutic_procedure
.	O

-DOCSTART- -X- -X- -X- O

An	O
81	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
female	O
with	O
hypertension	O
and	O
gout	O
was	O
admitted	O
to	O
Taichung	B-Nonbiological_location
Veterans	I-Nonbiological_location
General	I-Nonbiological_location
Hospital	I-Nonbiological_location
due	O
to	O
abdominal	B-Biological_structure
pain	B-Sign_symptom
and	O
hematemesis	B-Sign_symptom
.	O

She	O
began	O
to	O
suffer	O
from	O
intermittent	B-Detailed_description
epigastralgia	B-Sign_symptom
more	O
than	O
10	O
years	O
ago	O
,	O
and	O
a	O
4	B-Distance
cm	I-Distance
gastric	B-Biological_structure
tumor	B-Sign_symptom
was	O
found	O
.	O

The	O
abdominal	B-Biological_structure
pain	B-Sign_symptom
got	B-Lab_value
worse	I-Lab_value
2	O
years	O
before	O
admission	O
,	O
and	O
she	O
went	O
to	O
a	O
local	B-Nonbiological_location
hospital	I-Nonbiological_location
where	O
abdominal	B-Biological_structure
CT	B-Diagnostic_procedure
scan	O
revealed	O
a	O
gastric	B-Biological_structure
tumor	B-Sign_symptom
about	O
6	B-Distance
cm	I-Distance
in	O
length	O
with	O
well	B-Detailed_description
-	I-Detailed_description
circumscribed	I-Detailed_description
calcification	I-Detailed_description
(	O
figure	O
1	O
)	O
.	O

Surgical	B-Therapeutic_procedure
intervention	I-Therapeutic_procedure
was	O
suggested	O
,	O
but	O
she	O
declined	O
.	O

About	O
10	O
days	O
before	O
admission	O
,	O
tarry	B-Sign_symptom
stool	I-Sign_symptom
passage	O
was	O
noted	O
,	O
and	O
bloody	B-Sign_symptom
vomitus	I-Sign_symptom
was	O
found	O
1	O
day	O
later	O
.	O

UGI	B-Diagnostic_procedure
scope	I-Diagnostic_procedure
revealed	O
submucosal	B-Biological_structure
gastric	B-Biological_structure
tumor	B-Sign_symptom
with	O
central	B-Detailed_description
ulceration	I-Detailed_description
and	O
she	O
was	O
then	O
transferred	O
to	O
our	O
hospital	B-Nonbiological_location
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
upper	B-Biological_structure
abdominal	I-Biological_structure
tenderness	B-Sign_symptom
with	O
mild	B-Severity
muscle	B-Biological_structure
guarding	B-Sign_symptom
.	O

The	O
plain	B-Detailed_description
radiography	B-Diagnostic_procedure
showed	O
an	O
irregular	B-Shape
shape	I-Shape
calcification	B-Sign_symptom
over	O
upper	B-Biological_structure
abdomen	I-Biological_structure
.	O

UGI	B-Diagnostic_procedure
scope	I-Diagnostic_procedure
revealed	O
deep	B-Biological_structure
gastric	I-Biological_structure
ulcer	B-Sign_symptom
with	O
foreign	B-Sign_symptom
body	I-Sign_symptom
.	O

CT	B-Diagnostic_procedure
scan	O
showed	O
an	O
irregularly	B-Shape
shaped	I-Shape
space	B-Detailed_description
-	I-Detailed_description
occupying	I-Detailed_description
lesion	B-Sign_symptom
in	O
front	O
of	O
the	O
stomach	B-Biological_structure
with	O
plate	B-Detailed_description
calcifications	I-Detailed_description
and	O
localized	B-Detailed_description
free	B-Sign_symptom
air	I-Sign_symptom
(	O
figures	O
2	O
and	O
3	O
)	O
.	O

Under	O
the	O
impression	O
of	O
perforated	O
gastric	O
tumor	O
,	O
emergent	B-Detailed_description
laparotomy	B-Diagnostic_procedure
was	O
performed	O
.	O

An	O
infiltrative	B-Detailed_description
mass	B-Sign_symptom
between	O
the	O
stomach	B-Biological_structure
and	O
transverse	B-Biological_structure
colon	I-Biological_structure
was	O
noted	O
during	O
operation	O
.	O

A	O
sharp	B-Detailed_description
,	O
bone	B-Detailed_description
-	I-Detailed_description
like	I-Detailed_description
and	O
thick	B-Detailed_description
calcified	B-Sign_symptom
plate	I-Sign_symptom
penetrating	O
into	O
the	O
gastric	B-Biological_structure
mucosa	I-Biological_structure
and	O
pericolic	B-Biological_structure
soft	I-Biological_structure
tissue	I-Biological_structure
was	O
observed	O
.	O

A	O
submucosal	B-Biological_structure
tumor	B-Sign_symptom
about	O
2	B-Distance
.	I-Distance
3	I-Distance
cm	I-Distance
in	O
size	O
adherent	O
to	O
the	O
calcified	O
plate	O
was	O
also	O
noted	O
(	O
figures	O
4	O
and	O
5	O
)	O
.	O

Distal	B-Detailed_description
subtotal	B-Detailed_description
gastrectomy	B-Therapeutic_procedure
and	O
partial	B-Detailed_description
colectomy	B-Therapeutic_procedure
were	O
performed	O
.	O

The	O
patient	O
was	O
discharged	O
13	O
days	O
after	O
operation	O
uneventfully	O
.	O

Microscopically	B-Diagnostic_procedure
,	O
spindle	B-Shape
-	I-Shape
shaped	I-Shape
tumor	B-Sign_symptom
cells	I-Sign_symptom
with	O
low	B-Lab_value
mitotic	B-Diagnostic_procedure
frequency	I-Diagnostic_procedure
(	O
4	B-Lab_value
/	I-Lab_value
50	I-Lab_value
HPF	I-Lab_value
)	O
were	O
found	O
.	O

Immunohistochemical	B-Diagnostic_procedure
staining	I-Diagnostic_procedure
of	O
the	O
tumor	O
demonstrated	O
diffusely	B-Lab_value
strong	I-Lab_value
positive	I-Lab_value
reactivity	O
for	O
CD	B-Diagnostic_procedure
117	I-Diagnostic_procedure
,	O
positive	B-Lab_value
reactivity	O
for	O
CD34	B-Diagnostic_procedure
,	O
but	O
negative	B-Lab_value
reactivity	O
for	O
S100	B-Diagnostic_procedure
protein	I-Diagnostic_procedure
and	O
desmin	B-Diagnostic_procedure
.	O

The	O
diagnosis	O
of	O
the	O
tumor	O
was	O
established	O
as	O
GIST	B-Disease_disorder
.	O

Due	O
to	O
the	O
small	O
size	O
and	O
the	O
paucity	O
of	O
mitotic	O
figures	O
of	O
the	O
tumor	O
located	O
in	O
the	O
stomach	O
,	O
it	O
was	O
classified	O
as	O
very	B-Lab_value
low	I-Lab_value
risk	I-Lab_value
[	O
4	O
]	O
.	O

Sporadic	O
GIST	O
was	O
impressed	O
due	O
to	O
no	O
family	O
history	O
of	O
GIST	O
nor	O
other	O
GIST	O
presented	O
in	O
this	O
patient	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
36	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
female	O
presented	O
at	O
the	O
emergency	B-Nonbiological_location
department	I-Nonbiological_location
with	O
aggravating	B-Detailed_description
right	B-Biological_structure
upper	I-Biological_structure
abdominal	I-Biological_structure
pain	B-Sign_symptom
for	O
2	B-Duration
hours	I-Duration
.	O

The	O
patient	O
was	O
diagnosed	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
carrier	O
for	O
several	O
years	O
and	O
non	O
-	O
alcoholics	O
.	O

No	O
other	O
specific	O
personal	O
and	O
familial	O
medical	O
history	O
was	O
noted	O
.	O

Initial	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
100	B-Lab_value
/	I-Lab_value
60	I-Lab_value
mmHg	I-Lab_value
,	O
pulse	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
70	B-Lab_value
/	I-Lab_value
min	I-Lab_value
,	O
respiration	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
20	B-Lab_value
/	I-Lab_value
min	I-Lab_value
,	O
body	B-Diagnostic_procedure
temperature	I-Diagnostic_procedure
37	B-Lab_value
.	I-Lab_value
5	I-Lab_value
℃	I-Lab_value
.	O

The	O
laboratory	B-Diagnostic_procedure
findings	I-Diagnostic_procedure
were	O
white	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cell	I-Diagnostic_procedure
12,000	B-Lab_value
/	I-Lab_value
mm3	I-Lab_value
(	O
poly	B-Diagnostic_procedure
:	O
70	B-Lab_value
%	I-Lab_value
)	O
,	O
hemoglobin	B-Diagnostic_procedure
12	B-Lab_value
.	I-Lab_value
8	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
platelet	B-Diagnostic_procedure
198,000	B-Lab_value
/	I-Lab_value
mm3	I-Lab_value
,	O
prothrombin	B-Diagnostic_procedure
time	I-Diagnostic_procedure
14	B-Lab_value
.	I-Lab_value
3	I-Lab_value
seconds	I-Lab_value
,	O
international	B-Diagnostic_procedure
normalized	I-Diagnostic_procedure
ratio	I-Diagnostic_procedure
1	B-Lab_value
.	I-Lab_value
11	I-Lab_value
,	O
aspartate	B-Diagnostic_procedure
aminotransferase	I-Diagnostic_procedure
22	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
alanine	B-Diagnostic_procedure
aminotransferase	I-Diagnostic_procedure
12	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
total	B-Diagnostic_procedure
bilirubin	I-Diagnostic_procedure
0	B-Lab_value
.	I-Lab_value
5	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
alkaline	B-Diagnostic_procedure
phosphatase	I-Diagnostic_procedure
134	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
lactate	B-Diagnostic_procedure
dehydrogenase	I-Diagnostic_procedure
295	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
gamma	B-Diagnostic_procedure
-	I-Diagnostic_procedure
glutamyl	I-Diagnostic_procedure
transpeptidase	I-Diagnostic_procedure
26	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
protein	B-Diagnostic_procedure
/	I-Diagnostic_procedure
albumin	I-Diagnostic_procedure
6	B-Lab_value
.	I-Lab_value
4	I-Lab_value
/	I-Lab_value
4	I-Lab_value
.	I-Lab_value
0	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
uric	B-Diagnostic_procedure
acid	I-Diagnostic_procedure
5	B-Lab_value
.	I-Lab_value
0	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
blood	B-Diagnostic_procedure
urea	I-Diagnostic_procedure
nitrogen	I-Diagnostic_procedure
/	I-Diagnostic_procedure
creatinine	I-Diagnostic_procedure
16	B-Lab_value
.	I-Lab_value
6	I-Lab_value
/	I-Lab_value
0	I-Lab_value
.	I-Lab_value
7	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
.	O

And	O
serum	B-Diagnostic_procedure
viral	I-Diagnostic_procedure
markers	I-Diagnostic_procedure
were	O
HBsAg	B-Diagnostic_procedure
(	O
+	B-Lab_value
)	O
,	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
HBs	I-Diagnostic_procedure
(	O
-	B-Lab_value
)	O
,	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
HBc	I-Diagnostic_procedure
(	O
+	B-Lab_value
)	O
,	O
HBeAg	B-Diagnostic_procedure
(	O
-	B-Lab_value
)	O
,	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
HBe	I-Diagnostic_procedure
(	O
+	B-Lab_value
)	O
,	O
HBV	B-Diagnostic_procedure
-	I-Diagnostic_procedure
DNA	I-Diagnostic_procedure
<	B-Lab_value
20	I-Lab_value
IU	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
,	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
HCV	I-Diagnostic_procedure
(	O
-	B-Lab_value
)	O
and	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
HIV	I-Diagnostic_procedure
(	O
-	B-Lab_value
)	O
.	O

The	O
patient	O
`	O
s	O
serum	B-Diagnostic_procedure
α	I-Diagnostic_procedure
-	I-Diagnostic_procedure
fetoprotein	I-Diagnostic_procedure
(	O
AFP	B-Diagnostic_procedure
)	O
was	O
676	B-Lab_value
.	I-Lab_value
5	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
and	O
carbohydrate	B-Diagnostic_procedure
antigen	I-Diagnostic_procedure
19	I-Diagnostic_procedure
-	I-Diagnostic_procedure
9	I-Diagnostic_procedure
(	O
CA19	B-Diagnostic_procedure
-	I-Diagnostic_procedure
9	I-Diagnostic_procedure
)	O
<	B-Lab_value
0	I-Lab_value
.	I-Lab_value
6	I-Lab_value
U	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
.	O

She	O
took	O
an	O
abdominal	B-Biological_structure
CT	B-Diagnostic_procedure
scan	O
,	O
which	O
showed	O
a	O
9	B-Distance
cm	I-Distance
sized	O
necrotic	B-Detailed_description
mass	B-Sign_symptom
with	B-Detailed_description
internal	I-Detailed_description
hemorrhage	I-Detailed_description
at	O
the	O
right	B-Biological_structure
hepatic	I-Biological_structure
lobe	I-Biological_structure
and	O
ruptured	B-Biological_structure
to	I-Biological_structure
peritoneum	I-Biological_structure
(	O
Fig	O
.	O
1A	O
)	O
,	O
so	O
an	O
emergency	B-Detailed_description
hepatic	B-Biological_structure
central	I-Biological_structure
bisectionectomy	B-Therapeutic_procedure
was	O
done	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

The	O
initial	O
histological	O
diagnosis	O
was	O
cHCC	B-Disease_disorder
-	I-Disease_disorder
CC	I-Disease_disorder
with	O
spindle	B-Detailed_description
cell	I-Detailed_description
metaplasia	I-Detailed_description
of	I-Detailed_description
cholangiocarcinoma	I-Detailed_description
element	I-Detailed_description
(	O
Fig	O
.	O
2B	O
)	O
.	O

The	O
serum	B-Diagnostic_procedure
AFP	I-Diagnostic_procedure
was	O
decreased	B-Lab_value
to	O
7	B-Lab_value
.	I-Lab_value
67	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
at	O
time	O
of	O
discharge	O
.	O

Regarding	O
as	O
cHCC	B-Disease_disorder
-	I-Disease_disorder
CC	I-Disease_disorder
,	O
postoperative	O
adjuvant	B-Detailed_description
chemotherapy	B-Medication
with	O
tegafur	B-Medication
/	I-Medication
uracil	I-Medication
(	O
UFT	B-Medication
)	O
was	O
administrated	O
for	O
3	B-Duration
months	I-Duration
.	O

3	O
months	O
later	O
,	O
follow	O
-	O
up	O
abdominal	B-Biological_structure
CT	B-Diagnostic_procedure
scanning	O
showed	O
previously	O
unseen	O
a	O
5	B-Distance
.	I-Distance
5	I-Distance
cm	I-Distance
sized	O
left	B-Biological_structure
subphrenic	I-Biological_structure
mass	B-Sign_symptom
with	O
mild	B-Severity
enhancement	B-Sign_symptom
in	O
delayed	B-Detailed_description
image	I-Detailed_description
(	O
Fig	O
.	O
3A	O
,	O
B	O
)	O
and	O
AFP	B-Diagnostic_procedure
was	O
increased	B-Lab_value
to	O
312	B-Lab_value
.	I-Lab_value
06	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
.	O

She	O
underwent	O
laparoscopic	B-Detailed_description
splenectomy	B-Therapeutic_procedure
with	O
mass	B-Therapeutic_procedure
excision	I-Therapeutic_procedure
.	O

On	O
histologic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
mesenchymal	B-Diagnostic_procedure
elements	I-Diagnostic_procedure
consisted	O
of	O
a	O
proliferation	B-Lab_value
of	I-Lab_value
primitive	I-Lab_value
-	I-Lab_value
appearing	I-Lab_value
mesenchymal	I-Lab_value
spindle	I-Lab_value
-	I-Lab_value
shaped	I-Lab_value
cells	I-Lab_value
,	O
intimately	B-Detailed_description
admixed	I-Detailed_description
with	I-Detailed_description
the	I-Detailed_description
epithelial	I-Detailed_description
elements	I-Detailed_description
in	I-Detailed_description
a	I-Detailed_description
highly	I-Detailed_description
cellular	I-Detailed_description
pattern	I-Detailed_description
.	O

Cytoplasm	B-Diagnostic_procedure
was	O
more	B-Lab_value
abundant	I-Lab_value
than	I-Lab_value
that	I-Lab_value
of	I-Lab_value
mature	I-Lab_value
fibroblasts	I-Lab_value
,	O
and	O
the	O
nucleus	B-Diagnostic_procedure
was	O
elongated	B-Shape
and	O
plump	B-Shape
.	O

These	O
cells	B-Lab_value
blended	I-Lab_value
progressively	I-Lab_value
with	I-Lab_value
areas	I-Lab_value
of	I-Lab_value
less	I-Lab_value
intense	I-Lab_value
cellular	I-Lab_value
mesenchymal	I-Lab_value
proliferation	I-Lab_value
,	O
and	O
with	O
relatively	B-Detailed_description
acellular	I-Detailed_description
,	I-Detailed_description
fibrous	I-Detailed_description
septa	I-Detailed_description
.	O

Osteoid	B-Diagnostic_procedure
was	O
present	B-Lab_value
either	O
within	B-Detailed_description
the	I-Detailed_description
primitive	I-Detailed_description
mesenchyme	I-Detailed_description
,	O
near	B-Detailed_description
the	I-Detailed_description
fibrous	I-Detailed_description
septa	I-Detailed_description
or	I-Detailed_description
pseudocapsule	I-Detailed_description
,	O
or	O
admixed	B-Detailed_description
within	I-Detailed_description
the	I-Detailed_description
epithelial	I-Detailed_description
elements	I-Detailed_description
.	O

Osteoid	B-Diagnostic_procedure
foci	I-Diagnostic_procedure
contained	O
cells	B-Lab_value
morphologically	I-Lab_value
identical	I-Lab_value
to	I-Lab_value
osteoblasts	I-Lab_value
(	O
Fig	O
.	O
4A	O
)	O
.	O

The	O
immunohistochemistry	B-Diagnostic_procedure
stains	I-Diagnostic_procedure
showed	O
expression	B-Lab_value
of	O
hepatocyte	B-Diagnostic_procedure
,	O
β	B-Diagnostic_procedure
-	I-Diagnostic_procedure
HCG	I-Diagnostic_procedure
,	O
AFP	B-Diagnostic_procedure
,	O
vimentin	B-Diagnostic_procedure
,	O
CK7	B-Diagnostic_procedure
,	O
CK19	B-Diagnostic_procedure
,	O
CD56	B-Diagnostic_procedure
and	O
β	B-Diagnostic_procedure
-	I-Diagnostic_procedure
catenin	I-Diagnostic_procedure
and	O
negativity	B-Lab_value
for	O
CEA	B-Diagnostic_procedure
.	O
(	O
Fig	O
.	O
4B	O
,	O
C	O
,	O
D	O
,	O
E	O
,	O
F	O
,	O
G	O
)	O
.	O

Metastatic	B-Detailed_description
hepatoblastoma	B-Disease_disorder
was	O
confirmed	O
by	O
histologic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
with	O
immunohistochemistry	B-Diagnostic_procedure
stains	I-Diagnostic_procedure
,	O
so	O
immunohistochemistrically	O
re	O
-	O
examination	O
of	O
previous	O
surgical	O
specimens	O
was	O
also	O
confirmed	O
as	O
hepatoblastoma	O
.	O

Follow	O
-	O
up	O
abdominal	B-Biological_structure
CT	B-Diagnostic_procedure
scan	O
performed	O
1	O
month	O
after	O
reoperation	O
showed	O
a	O
newly	B-Detailed_description
onset	I-Detailed_description
1	B-Distance
.	I-Distance
7	I-Distance
cm	I-Distance
sized	O
subtle	B-Detailed_description
enhancing	I-Detailed_description
soft	B-Detailed_description
tissue	I-Detailed_description
mass	B-Sign_symptom
in	O
splenic	B-Biological_structure
bed	I-Biological_structure
,	O
and	O
positron	B-Diagnostic_procedure
emission	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
PET	B-Diagnostic_procedure
)	O
showed	O
multiple	B-Detailed_description
FDG	B-Detailed_description
uptake	B-Sign_symptom
(	O
max	B-Lab_value
SUV	I-Lab_value
>	I-Lab_value
3	I-Lab_value
.	I-Lab_value
80	I-Lab_value
)	O
in	O
left	B-Detailed_description
upper	I-Detailed_description
and	O
lower	B-Detailed_description
quadrant	I-Detailed_description
area	O
of	O
abdomen	B-Biological_structure
,	O
paralumbar	B-Biological_structure
area	I-Biological_structure
including	I-Biological_structure
right	I-Biological_structure
subphrenic	I-Biological_structure
area	I-Biological_structure
(	O
Fig	O
.	O
5A	O
,	O
B	O
,	O
C	O
)	O
.	O

Follow	O
-	O
up	O
AFP	B-Diagnostic_procedure
was	O
162	B-Lab_value
.	I-Lab_value
69	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
.	O

Systemic	B-Detailed_description
chemotherapy	B-Medication
started	O
with	O
cisplatin	B-Medication
(	O
60	B-Dosage
mg	I-Dosage
/	I-Dosage
m2	I-Dosage
)	O
,	O
5	B-Medication
-	I-Medication
fluorourasil	I-Medication
(	O
5	B-Medication
-	I-Medication
FU	I-Medication
)	O
(	O
600	B-Dosage
mg	I-Dosage
/	I-Dosage
m2	I-Dosage
)	O
,	O
vincristine	B-Medication
(	O
1	B-Dosage
.	I-Dosage
5	I-Dosage
mg	I-Dosage
/	I-Dosage
m2	I-Dosage
)	O
and	O
total	O
3	B-Frequency
cycles	I-Frequency
of	O
chemotherapy	O
were	O
done	O
every	B-Frequency
4	I-Frequency
week	I-Frequency
.	O

Entecavir	B-Medication
0	B-Dosage
.	I-Dosage
5	I-Dosage
mg	I-Dosage
was	O
also	O
started	O
for	O
chemoprophylaxis	B-Medication
of	O
CHB	B-Disease_disorder
.	O

After	O
the	O
3rd	O
chemotherapy	O
cycle	O
,	O
follow	O
-	O
up	O
abdominal	B-Biological_structure
CT	B-Diagnostic_procedure
and	O
PET	B-Diagnostic_procedure
scan	O
showed	O
progression	O
of	O
multiple	B-Detailed_description
intraperitoneal	B-Biological_structure
metastasis	B-Sign_symptom
with	O
large	B-Severity
amount	I-Severity
of	O
intraperitoneal	B-Biological_structure
fluid	B-Sign_symptom
(	O
Fig	O
.	O
6A	O
,	O
B	O
)	O
and	O
follow	O
-	O
up	O
AFP	B-Diagnostic_procedure
was	O
further	O
increased	B-Lab_value
to	O
254	B-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
.	O

So	O
chemotherapy	B-Medication
regimen	O
was	O
changed	O
to	O
carboplatin	B-Medication
(	O
350	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
m2	I-Lab_value
)	O
with	O
doxorubicin	B-Medication
(	O
30	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
m2	I-Lab_value
)	O
every	B-Frequency
3	I-Frequency
weeks	I-Frequency
.	O

The	O
patient	O
experienced	O
neutropenia	B-Sign_symptom
after	O
the	O
new	O
regimen	O
,	O
but	O
recovered	B-Sign_symptom
shortly	O
after	O
treatment	O
with	O
granulocyte	B-Medication
colony	I-Medication
-	I-Medication
stimulating	I-Medication
factor	I-Medication
(	O
G	B-Medication
-	I-Medication
CSF	I-Medication
)	O
.	O

After	O
second	O
carboplatin	O
with	O
doxorubicin	O
chemotherapy	O
,	O
follow	O
-	O
up	O
AFP	B-Diagnostic_procedure
was	O
increased	B-Lab_value
1510	B-Lab_value
.	I-Lab_value
19	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
,	O
but	O
abdominal	B-Biological_structure
CT	B-Diagnostic_procedure
scan	O
showed	O
that	O
amount	O
of	O
ascites	B-Sign_symptom
was	O
decreased	O
(	O
Fig	O
.	O
7	O
)	O
.	O

Because	O
of	O
radiologic	O
improvements	O
,	O
third	O
and	O
fourth	O
chemotherapy	B-Medication
were	O
performed	O
.	O

After	O
4th	O
chemotherapy	O
,	O
follow	O
-	O
up	O
abdominal	B-Biological_structure
CT	B-Diagnostic_procedure
revealed	O
progression	O
of	O
multiple	B-Detailed_description
intraperitoneal	B-Biological_structure
metastatic	B-Detailed_description
masses	B-Sign_symptom
,	O
newly	O
developed	O
hepatic	B-Biological_structure
metastasis	B-Sign_symptom
and	O
large	B-Severity
amount	I-Severity
of	O
intraperitoneal	B-Biological_structure
fluid	B-Sign_symptom
(	O
Fig	O
.	O
8	O
)	O
.	O

A	O
diagnostic	O
paracentesis	B-Diagnostic_procedure
was	O
performed	O
and	O
showed	O
white	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cell	I-Diagnostic_procedure
310	B-Lab_value
/	I-Lab_value
mm3	I-Lab_value
(	O
poly	B-Diagnostic_procedure
20	B-Lab_value
%	I-Lab_value
,	O
lymph	B-Diagnostic_procedure
80	B-Lab_value
%	I-Lab_value
)	O
,	O
protein	B-Diagnostic_procedure
3	B-Lab_value
.	I-Lab_value
6	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
and	O
albumin	B-Diagnostic_procedure
2	B-Lab_value
.	I-Lab_value
3	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
on	O
ascitic	B-Diagnostic_procedure
fluid	I-Diagnostic_procedure
analysis	I-Diagnostic_procedure
.	O

The	O
serum	B-Diagnostic_procedure
albumin	I-Diagnostic_procedure
was	O
3	B-Lab_value
.	I-Lab_value
1	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
and	O
serum	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ascites	I-Diagnostic_procedure
albumin	I-Diagnostic_procedure
gradient	I-Diagnostic_procedure
(	O
SAAG	B-Diagnostic_procedure
)	O
was	O
0	B-Lab_value
.	I-Lab_value
8	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
.	O

The	O
AFB	B-Diagnostic_procedure
stain	I-Diagnostic_procedure
and	I-Diagnostic_procedure
culture	I-Diagnostic_procedure
were	O
all	O
negative	B-Lab_value
in	O
ascitic	B-Detailed_description
fluid	I-Detailed_description
.	O

The	O
AFP	B-Diagnostic_procedure
was	O
6881	B-Lab_value
.	I-Lab_value
93	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
on	O
serum	B-Detailed_description
.	O

Regarded	O
as	O
peritoneal	B-Biological_structure
carcinomatosis	B-Disease_disorder
,	O
the	O
patient	O
underwent	O
conservative	B-Therapeutic_procedure
treatments	I-Therapeutic_procedure
including	O
the	O
use	O
of	O
repeated	B-Detailed_description
therapeutic	B-Therapeutic_procedure
paracentesis	I-Therapeutic_procedure
for	O
1	B-Duration
month	I-Duration
before	O
death	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
26	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
of	O
Portuguese	O
descent	O
with	O
no	O
significant	O
past	O
medical	O
history	O
presents	O
with	O
subacute	O
onset	O
of	O
right	B-Detailed_description
-	I-Detailed_description
sided	I-Detailed_description
hemiparesis	B-Sign_symptom
and	O
aphasia	B-Disease_disorder
,	O
with	O
marked	B-Severity
expressive	B-Detailed_description
aphasia	B-Disease_disorder
,	O
word	B-Sign_symptom
-	I-Sign_symptom
finding	I-Sign_symptom
difficulty	I-Sign_symptom
,	O
and	O
rare	B-Frequency
paraphrasic	B-Sign_symptom
errors	I-Sign_symptom
.	O

Examination	B-Diagnostic_procedure
demonstrated	O
right	B-Biological_structure
central	I-Biological_structure
facial	I-Biological_structure
weakness	B-Sign_symptom
,	O
2	B-Lab_value
-	I-Lab_value
3	I-Lab_value
/	I-Lab_value
5	I-Lab_value
strength	B-Diagnostic_procedure
in	O
the	O
right	B-Detailed_description
arm	B-Biological_structure
and	O
leg	B-Biological_structure
,	O
and	O
dysmetria	B-Sign_symptom
in	O
the	O
right	B-Detailed_description
upper	B-Detailed_description
and	O
lower	B-Detailed_description
extremities	B-Biological_structure
.	O

Reflexes	B-Diagnostic_procedure
were	O
hyperactive	B-Lab_value
on	O
the	O
right	B-Detailed_description
with	O
a	O
right	B-Lab_value
-	I-Lab_value
sided	I-Lab_value
Babinski	B-Diagnostic_procedure
response	I-Diagnostic_procedure
.	O

MRI	B-Diagnostic_procedure
of	O
the	O
brain	B-Biological_structure
showed	O
multiple	B-Detailed_description
bilateral	B-Detailed_description
concentric	B-Detailed_description
ring	B-Shape
-	I-Shape
like	I-Shape
structures	B-Sign_symptom
in	O
the	O
centrum	B-Biological_structure
semiovale	I-Biological_structure
and	O
the	O
corona	B-Biological_structure
radiata	I-Biological_structure
on	O
T2	B-Diagnostic_procedure
imaging	I-Diagnostic_procedure
(	O
figure	O
,	O
A	O
)	O
,	O
consistent	O
with	O
the	O
pattern	O
of	O
Balo	B-Disease_disorder
concentric	I-Disease_disorder
sclerosis	I-Disease_disorder
.	O

There	O
was	O
associated	B-Detailed_description
restricted	I-Detailed_description
diffusion	I-Detailed_description
in	O
3	B-Lab_value
lesions	B-Sign_symptom
and	O
incomplete	B-Detailed_description
ring	I-Detailed_description
enhancement	I-Detailed_description
in	O
1	B-Lab_value
lesion	B-Sign_symptom
.	O

CSF	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
showed	O
30	B-Lab_value
leukocytes	B-Diagnostic_procedure
(	O
79	B-Lab_value
%	I-Lab_value
lymphocytes	B-Diagnostic_procedure
,	O
4	B-Lab_value
%	I-Lab_value
monocytes	B-Diagnostic_procedure
)	O
,	O
erythrocyte	B-Diagnostic_procedure
count	O
was	O
850	B-Lab_value
,	O
and	O
oligoclonal	B-Diagnostic_procedure
bands	I-Diagnostic_procedure
were	O
absent	B-Lab_value
.	O

He	O
was	O
treated	O
with	O
1	B-Dosage
g	I-Dosage
of	O
IV	O
methylprednisolone	B-Medication
daily	B-Dosage
for	O
5	B-Duration
days	I-Duration
,	O
with	O
little	O
improvement	O
.	O

He	O
then	O
underwent	O
5	B-Lab_value
plasmapheresis	B-Therapeutic_procedure
exchanges	I-Therapeutic_procedure
,	O
with	O
significant	B-Lab_value
improvement	I-Lab_value
of	O
motor	B-Diagnostic_procedure
,	O
sensory	B-Diagnostic_procedure
,	O
speech	B-Disease_disorder
deficits	I-Disease_disorder
,	O
and	O
gait	B-Diagnostic_procedure
.	O

Forty	O
-	O
five	O
days	O
after	O
discharge	O
,	O
his	O
examination	B-Diagnostic_procedure
showed	O
4	B-Lab_value
+	I-Lab_value
/	I-Lab_value
5	I-Lab_value
strength	B-Diagnostic_procedure
in	O
the	O
right	B-Biological_structure
intrinsic	I-Biological_structure
muscles	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
hand	I-Biological_structure
and	O
a	O
right	B-Detailed_description
-	I-Detailed_description
sided	I-Detailed_description
positional	B-Sign_symptom
tremor	I-Sign_symptom
.	O

Gait	B-Diagnostic_procedure
and	O
tandem	B-Detailed_description
gait	B-Diagnostic_procedure
were	O
normal	B-Lab_value
.	O

He	O
was	O
placed	O
on	O
β	B-Medication
-	I-Medication
interferon	I-Medication
-	I-Medication
1a	I-Medication
44	B-Dosage
μg	I-Dosage
subcutaneously	O
3	B-Dosage
times	I-Dosage
a	I-Dosage
week	I-Dosage
,	O
for	O
treatment	O
of	O
presumed	O
clinically	B-Disease_disorder
isolated	I-Disease_disorder
syndrome	I-Disease_disorder
,	O
with	O
good	B-Lab_value
response	B-Diagnostic_procedure
.	O

One	O
year	O
later	O
,	O
his	O
neurologic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
was	O
essentially	B-Lab_value
normal	I-Lab_value
.	O

There	O
was	O
no	O
family	O
history	O
of	O
demyelinating	O
or	O
autoimmune	O
disorders	O
.	O

His	O
mother	O
has	O
a	O
significant	O
history	O
of	O
headaches	O
and	O
early	O
-	O
onset	O
strokes	O
,	O
and	O
was	O
found	O
to	O
be	O
a	O
carrier	O
of	O
the	O
Notch3	O
mutation	O
consistent	O
with	O
cerebral	O
autosomal	O
dominant	O
arteriopathy	O
with	O
subcortical	O
infarcts	O
and	O
leukoencephalopathy	O
(	O
CADASIL	O
)	O
.	O

His	O
sister	O
had	O
a	O
stroke	O
in	O
her	O
30s	O
,	O
and	O
a	O
history	O
of	O
migraine	O
headaches	O
,	O
but	O
has	O
not	O
undergone	O
medical	O
evaluation	O
.	O

Testing	B-Diagnostic_procedure
for	I-Diagnostic_procedure
CADASIL	I-Diagnostic_procedure
in	O
the	O
patient	O
showed	B-Lab_value
the	O
Notch3	B-Diagnostic_procedure
mutation	I-Diagnostic_procedure
associated	B-Detailed_description
with	I-Detailed_description
CADASIL	I-Detailed_description
(	O
transition	B-Detailed_description
C	I-Detailed_description
>	I-Detailed_description
T	I-Detailed_description
,	I-Detailed_description
nucleotide	I-Detailed_description
position	I-Detailed_description
1750	I-Detailed_description
,	I-Detailed_description
codon	I-Detailed_description
558	I-Detailed_description
)	O
.	O

Skin	B-Biological_structure
biopsy	B-Diagnostic_procedure
showed	O
electron	B-Detailed_description
-	I-Detailed_description
dense	I-Detailed_description
extracellular	B-Detailed_description
material	B-Sign_symptom
in	O
close	O
apposition	O
to	O
the	O
smooth	B-Biological_structure
muscle	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
vascular	I-Biological_structure
media1	I-Biological_structure
(	O
figure	O
,	O
B	O
)	O
.	O

-DOCSTART- -X- -X- -X- O

The	O
31	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
white	O
primipara	O
with	O
twin	O
pregnancy	O
was	O
admitted	O
to	O
hospital	O
in	O
the	O
38th	O
week	O
of	O
gestation	O
with	O
elevated	B-Sign_symptom
blood	I-Sign_symptom
pressure	I-Sign_symptom
(	O
150	B-Lab_value
/	I-Lab_value
100	I-Lab_value
mmHg	I-Lab_value
)	O
.	O

After	O
receiving	O
antihypertensive	B-Medication
treatment	I-Medication
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
120	B-Lab_value
/	I-Lab_value
80	I-Lab_value
.	O

All	O
laboratory	B-Diagnostic_procedure
variables	I-Diagnostic_procedure
,	I-Diagnostic_procedure
including	I-Diagnostic_procedure
plasma	I-Diagnostic_procedure
proteins	I-Diagnostic_procedure
,	O
were	O
within	B-Lab_value
their	I-Lab_value
respective	I-Lab_value
reference	I-Lab_value
intervals	I-Lab_value
.	O

Few	B-Time
hours	I-Time
after	I-Time
admission	I-Time
to	I-Time
the	I-Time
hospital	I-Time
the	O
contractions	B-Sign_symptom
started	I-Sign_symptom
,	O
and	O
the	O
caesarean	B-Therapeutic_procedure
section	I-Therapeutic_procedure
was	O
performed	O
because	O
of	O
vertex	B-Sign_symptom
-	I-Sign_symptom
transverse	I-Sign_symptom
presentation	I-Sign_symptom
of	I-Sign_symptom
twins	I-Sign_symptom
.	O

Liveborn	O
female	O
and	O
male	O
were	O
delivered	B-Therapeutic_procedure
.	O

The	O
postoperative	B-Detailed_description
course	I-Detailed_description
was	O
initially	O
inconspicuous	B-Sign_symptom
.	O

Four	B-Time
hours	I-Time
postpartum	I-Time
she	O
experienced	O
sudden	B-Detailed_description
epigastric	B-Sign_symptom
pain	I-Sign_symptom
.	O

The	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
rose	O
to	O
190	B-Lab_value
/	I-Lab_value
130	I-Lab_value
.	O

Laboratory	B-Diagnostic_procedure
findings	I-Diagnostic_procedure
showed	O
haemolysis	B-Sign_symptom
,	O
thrombocytopenia	B-Sign_symptom
,	O
and	O
an	O
increase	B-Lab_value
in	O
serum	B-Diagnostic_procedure
creatinine	I-Diagnostic_procedure
and	O
aminotransferases	B-Diagnostic_procedure
(	O
Table	O
I	O
)	O
.	O

Intravenous	O
magnesium	B-Medication
sulphate	I-Medication
was	O
administered	O
.	O

Abdominal	B-Diagnostic_procedure
ultrasound	I-Diagnostic_procedure
disclosed	O
an	O
empty	B-Detailed_description
uterine	B-Biological_structure
cavity	I-Biological_structure
without	O
placenta	B-Sign_symptom
residue	I-Sign_symptom
.	O

Five	B-Time
hours	I-Time
postpartum	I-Time
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
intensive	B-Nonbiological_location
care	I-Nonbiological_location
unit	I-Nonbiological_location
because	O
of	O
poor	B-Sign_symptom
urine	I-Sign_symptom
output	I-Sign_symptom
,	O
drowsiness	B-Sign_symptom
,	O
and	O
suspicion	B-Detailed_description
of	O
DIC	B-Disease_disorder
.	O

On	O
examination	B-Diagnostic_procedure
she	O
was	O
sleepy	B-Sign_symptom
and	O
disoriented	B-Sign_symptom
.	O

The	O
combination	O
of	O
haemolysis	O
,	O
thrombocytopenia	O
,	O
and	O
elevated	O
liver	O
enzymes	O
suggested	O
a	O
postpartum	B-Disease_disorder
HELLP	I-Disease_disorder
syndrome	I-Disease_disorder
,	O
complicated	O
by	O
DIC	O
.	O

The	O
patient	O
was	O
rehydrated	B-Therapeutic_procedure
,	O
and	O
treatment	B-Therapeutic_procedure
was	O
instituted	O
with	O
fresh	B-Detailed_description
frozen	B-Detailed_description
plasma	B-Therapeutic_procedure
,	O
red	B-Biological_structure
cell	I-Biological_structure
transfusion	B-Therapeutic_procedure
,	O
fresh	B-Detailed_description
platelets	B-Therapeutic_procedure
,	O
and	O
kybernin	B-Therapeutic_procedure
P	I-Therapeutic_procedure
(	O
antithrombin	O
III	O
)	O
.	O

High	B-Lab_value
serum	B-Diagnostic_procedure
urea	I-Diagnostic_procedure
,	O
creatinine	B-Diagnostic_procedure
,	O
and	O
persistent	B-Detailed_description
anuria	B-Sign_symptom
were	O
compatible	O
with	O
acute	B-Detailed_description
renal	B-Disease_disorder
failure	I-Disease_disorder
.	O

A	O
high	B-Dosage
dose	I-Dosage
of	O
furosemide	B-Medication
failed	O
to	O
increase	B-Therapeutic_procedure
diuresis	I-Therapeutic_procedure
.	O

Sixteen	B-Time
hours	I-Time
postpartum	I-Time
her	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
60	B-Lab_value
/	I-Lab_value
40	I-Lab_value
and	O
oxygen	B-Diagnostic_procedure
saturation	I-Diagnostic_procedure
70	B-Lab_value
%	I-Lab_value
.	O

Few	B-Time
minutes	I-Time
later	I-Time
the	O
patient	O
had	O
acute	B-Detailed_description
cardiac	B-Disease_disorder
arrest	I-Disease_disorder
,	O
and	O
resuscitation	B-Therapeutic_procedure
started	O
.	O

Resuscitation	O
was	O
successful	B-Detailed_description
,	O
and	O
normal	B-Sign_symptom
heart	I-Sign_symptom
action	I-Sign_symptom
was	O
re	O
-	O
established	O
;	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
rose	O
to	O
150	B-Lab_value
/	I-Lab_value
110	I-Lab_value
,	O
and	O
oxygen	B-Diagnostic_procedure
saturation	I-Diagnostic_procedure
was	O
90	B-Lab_value
%	I-Lab_value
.	O

Laboratory	B-Diagnostic_procedure
findings	I-Diagnostic_procedure
were	O
deteriorated	B-Lab_value
,	O
and	O
development	O
of	O
acute	B-Detailed_description
renal	O
failure	O
indicated	O
the	O
necessity	O
of	O
urgent	B-Detailed_description
dialysis	B-Therapeutic_procedure
.	O

Following	B-Time
dialysis	I-Time
,	O
the	O
patient	O
was	O
stable	B-Sign_symptom
,	O
oxygen	B-Diagnostic_procedure
saturation	I-Diagnostic_procedure
98	B-Lab_value
%	I-Lab_value
.	O

Twenty	B-Time
hours	I-Time
postpartum	I-Time
patient	O
developed	O
again	O
cardiopulmonary	B-Disease_disorder
arrest	I-Disease_disorder
.	O

Despite	O
resuscitation	B-Therapeutic_procedure
attempts	I-Therapeutic_procedure
the	O
outcome	O
was	O
lethal	O
.	O

Due	O
to	O
the	O
fact	O
that	O
death	O
occurred	O
in	O
the	O
hospital	B-Nonbiological_location
a	O
short	B-Time
time	I-Time
after	I-Time
a	I-Time
surgical	I-Time
intervention	I-Time
,	O
a	O
medico	B-Diagnostic_procedure
-	I-Diagnostic_procedure
legal	I-Diagnostic_procedure
autopsy	I-Diagnostic_procedure
was	O
ordered	O
.	O

An	O
autopsy	O
revealed	O
oedema	B-Sign_symptom
of	O
the	O
brain	B-Biological_structure
and	O
lungs	B-Biological_structure
as	O
well	O
as	O
dilatation	B-Sign_symptom
of	O
right	B-Biological_structure
and	I-Biological_structure
left	I-Biological_structure
ventricles	I-Biological_structure
.	O

Hydrothorax	B-Sign_symptom
(	O
900	B-Lab_value
mL	I-Lab_value
)	O
,	O
hydroperitoneum	B-Sign_symptom
(	O
2500	B-Lab_value
mL	I-Lab_value
)	O
,	O
and	O
hydropericardium	B-Sign_symptom
(	O
200	B-Lab_value
mL	I-Lab_value
)	O
were	O
present	O
.	O

The	O
field	O
of	O
operation	O
of	O
the	O
caesarean	B-Therapeutic_procedure
section	I-Therapeutic_procedure
was	O
unremarkable	B-Sign_symptom
.	O

Petechial	B-Sign_symptom
and	I-Sign_symptom
suffusional	I-Sign_symptom
haemorrhages	I-Sign_symptom
were	O
observed	O
under	O
the	O
pleura	B-Biological_structure
,	O
endocardium	B-Biological_structure
,	O
in	O
the	O
mucosae	B-Biological_structure
of	O
the	O
renal	B-Biological_structure
pelvis	I-Biological_structure
,	O
and	O
peritoneum	B-Biological_structure
of	O
the	O
small	B-Biological_structure
and	I-Biological_structure
large	I-Biological_structure
bowel	I-Biological_structure
.	O

Histology	B-Diagnostic_procedure
revealed	O
periportal	B-Detailed_description
hepatocellular	B-Biological_structure
necrosis	B-Sign_symptom
,	O
bloodless	B-Sign_symptom
glomeruli	B-Biological_structure
with	I-Sign_symptom
swollen	B-Detailed_description
and	I-Sign_symptom
vacuolated	B-Detailed_description
intracapillary	B-Biological_structure
cells	I-Biological_structure
,	O
as	O
well	O
as	O
confluent	B-Detailed_description
haemorrhages	B-Sign_symptom
in	O
kidneys	B-Biological_structure
,	O
liver	B-Biological_structure
,	O
and	O
spleen	B-Biological_structure
.	O

Death	O
was	O
attributed	O
to	O
multiple	B-Detailed_description
organ	B-Disease_disorder
failure	I-Disease_disorder
due	O
to	O
DIC	B-Disease_disorder
as	O
a	O
consequence	O
of	O
HELLP	B-Disease_disorder
syndrome	I-Disease_disorder
.	O

-DOCSTART- -X- -X- -X- O

A	O
41	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
Caucasian	O
woman	O
underwent	O
a	O
primary	B-Detailed_description
double	B-Detailed_description
lung	B-Therapeutic_procedure
transplantation	I-Therapeutic_procedure
for	O
cystic	O
fibrosis	O
in	O
2006	O
.	O

Her	O
medical	O
history	O
was	O
otherwise	O
unremarkable	O
and	O
the	O
patient	O
had	O
no	O
known	O
history	O
of	O
pulmonary	O
tuberculosis	O
or	O
tuberculosis	O
contact	O
.	O

On	O
December	O
2015	O
,	O
she	O
underwent	O
retransplantation	B-Therapeutic_procedure
for	O
chronic	B-Detailed_description
lung	B-Disease_disorder
allograft	I-Disease_disorder
dysfunction	I-Disease_disorder
.	O

During	O
the	O
month	O
preceding	O
retransplantation	O
,	O
4	B-Lab_value
sputum	B-Diagnostic_procedure
specimens	I-Diagnostic_procedure
remained	O
negative	B-Lab_value
for	O
acid	B-Detailed_description
-	I-Detailed_description
fast	I-Detailed_description
bacilli	I-Detailed_description
and	O
specific	B-Detailed_description
M	I-Detailed_description
.	I-Detailed_description
tuberculosis	I-Detailed_description
culture	I-Detailed_description
and	O
real	B-Detailed_description
-	I-Detailed_description
time	I-Detailed_description
polymerase	B-Diagnostic_procedure
chain	I-Diagnostic_procedure
reaction	I-Diagnostic_procedure
(	O
PCR	B-Diagnostic_procedure
)	O
testing	O
.	O

On	O
postoperative	O
day	O
42	O
,	O
deterioration	B-Lab_value
of	O
her	O
respiratory	B-Diagnostic_procedure
status	I-Diagnostic_procedure
prompted	O
a	O
chest	B-Biological_structure
-	O
computerized	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
scan	O
revealing	O
sub	B-Detailed_description
-	I-Detailed_description
centimeter	I-Detailed_description
bilateral	B-Detailed_description
nodules	B-Sign_symptom
primarily	O
located	O
in	O
the	O
apical	B-Biological_structure
posterior	I-Biological_structure
lobes	I-Biological_structure
and	O
a	O
bilateral	B-Detailed_description
pleural	B-Disease_disorder
effusion	I-Disease_disorder
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
same	O
day	O
,	O
a	O
bronchoalveolar	B-Diagnostic_procedure
lavage	I-Diagnostic_procedure
(	O
BAL	B-Diagnostic_procedure
)	O
yielded	O
a	O
positive	B-Lab_value
real	B-Detailed_description
-	I-Detailed_description
time	I-Detailed_description
PCR	B-Diagnostic_procedure
for	O
rifampicin	B-Detailed_description
-	I-Detailed_description
susceptible	I-Detailed_description
M	I-Detailed_description
.	I-Detailed_description
tuberculosis	I-Detailed_description
,	O
confirmed	B-Lab_value
by	O
culture	B-Diagnostic_procedure
on	O
postoperative	O
day	O
62	O
.	O

Tuberculin	B-Diagnostic_procedure
skin	I-Diagnostic_procedure
test	I-Diagnostic_procedure
(	O
TST	B-Diagnostic_procedure
)	O
or	O
interferon	B-Diagnostic_procedure
-	I-Diagnostic_procedure
γ	I-Diagnostic_procedure
release	I-Diagnostic_procedure
assay	I-Diagnostic_procedure
(	O
IGRA	B-Diagnostic_procedure
)	O
test	O
were	O
not	O
performed	O
.	O

All	O
the	O
BALs	B-Diagnostic_procedure
performed	O
on	O
postoperative	O
period	O
yielded	O
no	B-Lab_value
other	I-Lab_value
pathogen	I-Lab_value
except	O
for	O
the	O
one	O
performed	O
on	O
day	O
60	O
that	O
cultured	O
Pseudomonas	B-Lab_value
aeruginosa	I-Lab_value
;	O
the	O
adjunctive	B-Detailed_description
antibiotic	B-Medication
therapy	I-Medication
was	O
imipenem	B-Medication
-	I-Medication
cilastatin	I-Medication
,	O
3	B-Dosage
g	I-Dosage
/	I-Dosage
d	I-Dosage
.	O

Histological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
a	O
lung	B-Biological_structure
biopsy	B-Diagnostic_procedure
performed	O
6	O
weeks	O
after	O
retransplantation	O
revealed	O
a	O
caseating	B-Lab_value
granuloma	I-Lab_value
and	O
necrosis	B-Lab_value
.	O

Acid	B-Lab_value
-	I-Lab_value
fast	I-Lab_value
bacilli	I-Lab_value
were	O
identified	O
as	O
rifampicin	B-Detailed_description
-	I-Detailed_description
susceptible	I-Detailed_description
M	I-Detailed_description
.	I-Detailed_description
tuberculosis	I-Detailed_description
by	O
real	B-Detailed_description
-	I-Detailed_description
time	I-Detailed_description
PCR	B-Diagnostic_procedure
.	O

On	O
postoperative	O
day	O
65	O
,	O
the	O
patient	O
`	O
s	O
status	B-Diagnostic_procedure
worsened	B-Lab_value
with	O
severe	B-Severity
hypoxemia	B-Sign_symptom
,	O
shock	B-Disease_disorder
unresponsive	O
to	O
high	B-Dosage
dose	I-Dosage
cathecolamines	B-Medication
,	O
and	O
multiorgan	B-Disease_disorder
failure	I-Disease_disorder
.	O

The	O
patient	O
died	O
on	O
postoperative	O
day	O
70	O
,	O
despite	O
treatment	O
combining	O
isoniazid	B-Medication
,	O
rifampicin	B-Medication
,	O
ethambutol	B-Medication
,	O
and	O
pyrazinamide	B-Medication
.	O

Retrospective	O
real	B-Detailed_description
-	I-Detailed_description
time	I-Detailed_description
PCR	B-Diagnostic_procedure
testing	O
of	O
the	O
explanted	B-Detailed_description
lung	I-Detailed_description
and	O
BALs	B-Detailed_description
performed	I-Detailed_description
on	I-Detailed_description
postoperative	I-Detailed_description
days	I-Detailed_description
1	I-Detailed_description
,	I-Detailed_description
7	I-Detailed_description
,	I-Detailed_description
and	I-Detailed_description
21	I-Detailed_description
remained	O
negative	B-Lab_value
.	O

The	O
organ	O
donor	O
died	B-Detailed_description
of	I-Detailed_description
posttraumatic	I-Detailed_description
intracerebral	I-Detailed_description
hemorrhage	I-Detailed_description
.	O

He	O
was	O
a	B-Detailed_description
47	I-Detailed_description
-	I-Detailed_description
year	I-Detailed_description
-	I-Detailed_description
old	I-Detailed_description
man	I-Detailed_description
with	O
no	B-Detailed_description
history	I-Detailed_description
of	I-Detailed_description
lung	I-Detailed_description
disease	I-Detailed_description
or	I-Detailed_description
risk	I-Detailed_description
factors	I-Detailed_description
for	I-Detailed_description
tuberculosis	I-Detailed_description
other	O
than	O
chronic	B-Detailed_description
alcohol	I-Detailed_description
use	I-Detailed_description
and	I-Detailed_description
smoking	I-Detailed_description
.	O

TST	B-Detailed_description
results	I-Detailed_description
were	I-Detailed_description
not	I-Detailed_description
available	I-Detailed_description
.	O

During	O
hospitalization	O
,	O
a	O
lung	B-Detailed_description
CT	I-Detailed_description
-	I-Detailed_description
scan	I-Detailed_description
showed	I-Detailed_description
no	I-Detailed_description
signs	I-Detailed_description
of	I-Detailed_description
active	I-Detailed_description
or	I-Detailed_description
previous	I-Detailed_description
tuberculosis	I-Detailed_description
and	O
no	B-Detailed_description
TST	I-Detailed_description
or	I-Detailed_description
IGRA	I-Detailed_description
test	I-Detailed_description
results	I-Detailed_description
were	I-Detailed_description
available	I-Detailed_description
.	O

Routine	O
cultures	B-Detailed_description
of	I-Detailed_description
per	I-Detailed_description
-	I-Detailed_description
transplantation	I-Detailed_description
right	I-Detailed_description
lung	I-Detailed_description
biopsy	I-Detailed_description
yielded	I-Detailed_description
Candida	I-Detailed_description
albicans	I-Detailed_description
.	O

Retrospective	O
M	B-Detailed_description
.	I-Detailed_description
tuberculosis	I-Detailed_description
real	I-Detailed_description
-	I-Detailed_description
time	I-Detailed_description
PCR	I-Detailed_description
yielded	I-Detailed_description
negative	I-Detailed_description
results	I-Detailed_description
on	I-Detailed_description
the	I-Detailed_description
left	I-Detailed_description
and	I-Detailed_description
right	I-Detailed_description
donor	I-Detailed_description
-	I-Detailed_description
lung	I-Detailed_description
biopsies	I-Detailed_description
.	O

Both	B-Detailed_description
kidneys	I-Detailed_description
from	O
the	O
same	O
donor	O
were	O
transplanted	B-Detailed_description
into	I-Detailed_description
2	I-Detailed_description
other	I-Detailed_description
recipients	I-Detailed_description
.	O

Six	B-Detailed_description
months	I-Detailed_description
after	I-Detailed_description
transplantation	I-Detailed_description
,	O
neither	B-Detailed_description
of	I-Detailed_description
the	I-Detailed_description
kidney	I-Detailed_description
recipients	I-Detailed_description
had	I-Detailed_description
developed	I-Detailed_description
any	I-Detailed_description
signs	I-Detailed_description
or	I-Detailed_description
symptoms	I-Detailed_description
suggestive	I-Detailed_description
of	I-Detailed_description
active	I-Detailed_description
tuberculosis	I-Detailed_description
.	O

-DOCSTART- -X- -X- -X- O

A	O
56	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
presented	O
with	O
a	O
2	B-Duration
-	I-Duration
year	I-Duration
history	O
of	O
dysphagia	O
.	O

He	O
was	O
diagnosed	O
with	O
a	O
middle	B-Biological_structure
thoracic	I-Biological_structure
oesophageal	B-Biological_structure
squamous	B-Disease_disorder
cell	I-Disease_disorder
carcinoma	I-Disease_disorder
by	O
both	O
a	O
gastroscopy	B-Diagnostic_procedure
and	O
a	O
biopsy	B-Diagnostic_procedure
.	O

A	O
chest	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
scan	O
showed	O
an	O
enlarged	B-Sign_symptom
azygos	B-Biological_structure
vein	I-Biological_structure
(	O
a	O
diameter	O
of	O
2	B-Distance
.	I-Distance
5	I-Distance
cm	I-Distance
)	O
that	O
was	O
a	O
continuation	B-Sign_symptom
of	O
the	O
IVC	B-Biological_structure
(	O
Fig	O
.	O
1a	O
,	O
b	O
)	O
.	O

A	O
CT	B-Diagnostic_procedure
scan	O
of	O
the	O
abdomen	B-Biological_structure
showed	O
a	O
defect	B-Sign_symptom
in	O
the	O
suprarenal	B-Biological_structure
segment	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
inferior	I-Biological_structure
vena	I-Biological_structure
cava	I-Biological_structure
and	O
direct	B-Detailed_description
drainage	B-Sign_symptom
of	O
the	O
hepatic	B-Biological_structure
vein	I-Biological_structure
into	O
the	O
right	B-Biological_structure
atrium	I-Biological_structure
.	O

After	O
consultation	O
with	O
the	O
thoracic	B-Nonbiological_location
surgery	I-Nonbiological_location
department	I-Nonbiological_location
clinicians	I-Nonbiological_location
and	O
the	O
anaesthesiology	B-Nonbiological_location
department	I-Nonbiological_location
,	O
we	O
decided	O
to	O
perform	O
a	O
McKeown	B-Detailed_description
oesophagectomy	B-Therapeutic_procedure
.	O

The	O
patient	O
was	O
anaesthetised	B-Therapeutic_procedure
with	O
a	O
double	B-Detailed_description
-	I-Detailed_description
lumen	I-Detailed_description
tube	I-Detailed_description
and	O
underwent	O
a	O
standard	B-Detailed_description
posterolateral	B-Detailed_description
thoracotomy	B-Therapeutic_procedure
by	O
traditional	B-Detailed_description
open	I-Detailed_description
surgery	I-Detailed_description
.	O

We	O
first	O
performed	O
the	O
jugular	B-Biological_structure
and	I-Biological_structure
femoral	I-Biological_structure
vein	I-Biological_structure
percutaneous	B-Detailed_description
puncture	I-Detailed_description
to	O
create	O
a	O
veno	B-Therapeutic_procedure
-	I-Therapeutic_procedure
venous	I-Therapeutic_procedure
bypass	I-Therapeutic_procedure
and	O
then	O
connected	O
the	O
pressure	B-Therapeutic_procedure
sensor	I-Therapeutic_procedure
system	I-Therapeutic_procedure
to	O
the	O
monitor	O
.	O

The	O
monitor	O
displayed	O
the	O
real	O
-	O
time	O
pressure	O
value	O
of	O
the	O
jugular	O
vein	O
and	O
the	O
femoral	O
vein	O
.	O

Macroscopically	B-Diagnostic_procedure
,	O
the	O
diameter	B-Diagnostic_procedure
of	O
the	O
azygos	B-Biological_structure
arch	I-Biological_structure
was	O
approximately	O
2	B-Distance
.	I-Distance
5	I-Distance
cm	I-Distance
(	O
Fig	O
.	O
1c	O
)	O
,	O
and	O
the	O
superior	B-Detailed_description
edge	I-Detailed_description
of	O
the	O
tumour	B-Sign_symptom
adhered	O
tightly	O
to	O
the	O
arch	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
azygos	I-Biological_structure
vein	I-Biological_structure
.	O

When	O
the	O
arch	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
azygos	I-Biological_structure
vein	I-Biological_structure
was	O
pulled	B-Therapeutic_procedure
with	O
a	O
rubber	B-Detailed_description
hose	I-Detailed_description
to	O
dissociate	O
it	O
from	O
the	O
carcinoma	O
,	O
the	O
monitor	O
showed	O
that	O
the	O
femoral	B-Biological_structure
vein	I-Biological_structure
pressure	B-Diagnostic_procedure
increased	B-Lab_value
to	O
52	B-Lab_value
mmH2O	I-Lab_value
;	O
the	O
pressure	O
returned	O
to	O
a	O
normal	B-Lab_value
value	I-Lab_value
when	O
we	O
opened	O
the	O
bypass	O
between	O
the	O
femoral	O
vein	O
and	O
the	O
jugular	O
vein	O
(	O
Fig	O
.	O
2	O
)	O
.	O

The	O
surgery	O
was	O
performed	O
smoothly	O
,	O
without	O
injury	B-Disease_disorder
to	O
the	O
azygos	B-Biological_structure
vein	I-Biological_structure
,	O
and	O
the	O
postoperative	B-Diagnostic_procedure
recovery	I-Diagnostic_procedure
was	O
uneventful	B-Lab_value
.	O

The	O
pathology	B-Diagnostic_procedure
of	O
the	O
resected	B-Detailed_description
specimen	I-Detailed_description
showed	O
a	O
poorly	B-Lab_value
differentiated	I-Lab_value
squamous	B-Disease_disorder
cell	I-Disease_disorder
carcinoma	I-Disease_disorder
and	O
no	O
evidence	O
of	O
malignancy	B-Sign_symptom
in	O
15	B-Lab_value
of	O
the	O
lymph	B-Biological_structure
nodes	I-Biological_structure
.	O

After	O
5	B-Duration
months	I-Duration
of	O
follow	O
-	O
up	O
,	O
the	O
patient	O
was	O
asymptomatic	B-Sign_symptom
,	O
with	O
no	O
evidence	O
of	O
recurrent	B-Disease_disorder
disease	I-Disease_disorder
either	O
clinically	O
or	O
on	O
CT	B-Diagnostic_procedure
.	O

-DOCSTART- -X- -X- -X- O

A	O
58	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
with	O
a	O
past	O
medical	O
history	O
of	O
poorly	B-Detailed_description
controlled	I-Detailed_description
hypertension	O
and	O
type	O
2	O
diabetes	O
,	O
presented	O
to	O
the	O
ICU	B-Nonbiological_location
for	O
a	O
cardiogenic	B-Disease_disorder
shock	I-Disease_disorder
complicating	O
acute	B-Detailed_description
myocardial	B-Disease_disorder
infarction	I-Disease_disorder
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
reduced	B-Lab_value
level	B-Diagnostic_procedure
of	I-Diagnostic_procedure
consciousness	I-Diagnostic_procedure
(	O
Glasgow	B-Diagnostic_procedure
Coma	I-Diagnostic_procedure
Scale	I-Diagnostic_procedure
10	B-Lab_value
/	I-Lab_value
15	I-Lab_value
)	O
and	O
weak	B-Lab_value
vital	B-Diagnostic_procedure
signs	I-Diagnostic_procedure
;	O
a	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
of	O
80	B-Lab_value
/	I-Lab_value
50	I-Lab_value
mmHg	I-Lab_value
,	O
80	B-Lab_value
%	I-Lab_value
of	O
oxygen	B-Diagnostic_procedure
saturation	I-Diagnostic_procedure
,	O
capillary	B-Detailed_description
blood	B-Diagnostic_procedure
glucose	I-Diagnostic_procedure
at	O
2	B-Lab_value
.	I-Lab_value
26	I-Lab_value
g	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
a	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
over	B-Lab_value
125	I-Lab_value
bpm	I-Lab_value
,	O
and	O
crackling	B-Sign_symptom
in	O
pulmonary	B-Diagnostic_procedure
auscultation	I-Diagnostic_procedure
.	O

Cardiovascular	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
neither	O
cardiac	B-Sign_symptom
murmur	I-Sign_symptom
nor	O
signs	B-Sign_symptom
of	I-Sign_symptom
right	I-Sign_symptom
heart	I-Sign_symptom
failure	I-Sign_symptom
.	O

ECG	B-Diagnostic_procedure
on	O
admission	O
showed	O
normal	B-Lab_value
sinus	B-Detailed_description
rhythm	B-Diagnostic_procedure
,	O
with	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
125	B-Lab_value
bpm	I-Lab_value
and	O
extended	B-Sign_symptom
ST	I-Sign_symptom
-	I-Sign_symptom
elevation	I-Sign_symptom
in	O
anterior	B-Detailed_description
territory	I-Detailed_description
.	O

Laboratory	B-Diagnostic_procedure
results	I-Diagnostic_procedure
demonstrated	O
Troponin	B-Diagnostic_procedure
I	I-Diagnostic_procedure
level	O
of	O
6	B-Lab_value
.	I-Lab_value
41	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
,	O
creatinine	B-Diagnostic_procedure
kinase	I-Diagnostic_procedure
(	O
CKMB	B-Diagnostic_procedure
)	O
was	O
67	B-Lab_value
UI	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
Lactate	B-Diagnostic_procedure
deshydrogenase	I-Diagnostic_procedure
was	O
281	B-Lab_value
UI	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
glucose	B-Diagnostic_procedure
level	O
2	B-Lab_value
.	I-Lab_value
70	I-Lab_value
g	I-Lab_value
/	I-Lab_value
l	I-Lab_value
,	O
urea	B-Diagnostic_procedure
0	B-Lab_value
.	I-Lab_value
40	I-Lab_value
g	I-Lab_value
/	I-Lab_value
l	I-Lab_value
and	O
creatinine	B-Diagnostic_procedure
18	B-Lab_value
.	I-Lab_value
6	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
L	I-Lab_value
.	O

The	O
patient	O
was	O
intubated	B-Therapeutic_procedure
and	O
sedated	B-Therapeutic_procedure
,	O
inotropic	B-Medication
agents	I-Medication
were	O
started	O
(	O
norepinephrine	B-Medication
0	B-Dosage
.	I-Dosage
4µg	I-Dosage
/	I-Dosage
kg	I-Dosage
/	I-Dosage
min	I-Dosage
and	O
dobutamine	B-Medication
20µg	B-Dosage
/	I-Dosage
kg	I-Dosage
/	I-Dosage
min	I-Dosage
)	O
.	O

Chest	B-Biological_structure
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
rays	I-Diagnostic_procedure
showed	O
diffuse	B-Detailed_description
alveolar	B-Disease_disorder
syndrome	I-Disease_disorder
.	O

Transthoracic	B-Biological_structure
echocardiography	B-Diagnostic_procedure
revealed	O
wall	B-Sign_symptom
motion	I-Sign_symptom
abnormalities	I-Sign_symptom
namely	O
extensive	B-Severity
akinesis	B-Sign_symptom
of	O
anteroseptal	B-Biological_structure
,	O
anterior	B-Biological_structure
,	O
lateral	B-Biological_structure
and	O
inferior	B-Biological_structure
walls	B-Biological_structure
,	O
and	O
severe	B-Severity
left	B-Sign_symptom
ventricular	I-Sign_symptom
systolic	I-Sign_symptom
dysfunction	I-Sign_symptom
(	O
ejection	B-Diagnostic_procedure
fraction	I-Diagnostic_procedure
of	O
29	B-Lab_value
%	I-Lab_value
)	O
.	O

Medical	B-Therapeutic_procedure
management	I-Therapeutic_procedure
was	O
initiated	O
;	O
anticoagulant	B-Medication
therapy	O
for	O
acute	B-Disease_disorder
coronary	I-Disease_disorder
syndrome	I-Disease_disorder
was	O
started	O
(	O
500	B-Dosage
mg	I-Dosage
of	O
acetylsalicylic	B-Medication
acid	I-Medication
and	O
subcutaneous	O
low	B-Medication
-	I-Medication
molecular	I-Medication
-	I-Medication
weight	I-Medication
heparin	I-Medication
(	O
0	B-Dosage
.	I-Dosage
6	I-Dosage
ml	I-Dosage
of	O
enoxaparin	B-Medication
)	O
)	O
and	O
patient	O
was	O
prepared	O
for	O
myocardial	B-Therapeutic_procedure
revascularization	I-Therapeutic_procedure
by	O
coronary	B-Biological_structure
angioplasty	B-Therapeutic_procedure
.	O

Because	O
of	O
non	B-Lab_value
-	I-Lab_value
improvement	I-Lab_value
of	O
neurological	B-Diagnostic_procedure
status	I-Diagnostic_procedure
and	O
occurrence	O
of	O
seizures	B-Sign_symptom
,	O
a	O
brain	B-Biological_structure
CT	B-Diagnostic_procedure
was	O
indicated	O
and	O
revealed	O
infratentorial	B-Biological_structure
diffuse	B-Detailed_description
hemorrhage	B-Sign_symptom
(	O
Fisher	B-Diagnostic_procedure
grade	I-Diagnostic_procedure
III	B-Lab_value
)	O
(	O
Figure	O
1	O
)	O
.	O

Cerebral	B-Biological_structure
angiography	B-Diagnostic_procedure
confirmed	O
a	O
dissecting	B-Disease_disorder
aneurysm	I-Disease_disorder
of	O
an	O
anastomotic	B-Biological_structure
branch	I-Biological_structure
between	O
left	B-Biological_structure
PICA	I-Biological_structure
and	O
the	O
V4	B-Biological_structure
segment	I-Biological_structure
of	I-Biological_structure
left	I-Biological_structure
vertebral	I-Biological_structure
artery	I-Biological_structure
Figure	O
2	O
that	O
was	O
successfully	O
embolized	B-Therapeutic_procedure
.	O

After	O
24	O
hours	O
,	O
the	O
patient	O
improved	B-Sign_symptom
with	O
withdrawal	O
of	O
vasoactive	B-Medication
drugs	I-Medication
in	O
24	O
hours	O
.	O

Left	B-Biological_structure
hemicorporeal	I-Biological_structure
seizures	B-Sign_symptom
persisted	O
despite	O
anticonvulsant	B-Medication
treatment	O
.	O

Control	O
brain	B-Biological_structure
CT	B-Diagnostic_procedure
did	O
not	O
report	O
rebleeding	B-Sign_symptom
and	O
angiography	B-Diagnostic_procedure
showed	O
complete	O
exclusion	O
of	O
the	O
aneurysm	B-Disease_disorder
while	O
the	O
EEG	B-Diagnostic_procedure
revealed	O
a	O
diffuse	B-Detailed_description
brain	B-Disease_disorder
damage	I-Disease_disorder
.	O

10	O
days	O
after	O
admission	O
,	O
the	O
patient	O
was	O
discharged	O
in	O
stable	B-Lab_value
condition	B-Diagnostic_procedure
but	O
still	O
suffers	O
from	O
amnesia	B-Disease_disorder
.	O

-DOCSTART- -X- -X- -X- O

A	B-Age
49	I-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
,	O
with	O
no	O
history	O
of	O
cardiac	O
disease	O
,	O
presented	O
with	O
progressive	B-Detailed_description
dyspnea	B-Sign_symptom
of	O
one	B-Duration
month	I-Duration
`	I-Duration
s	I-Duration
duration	I-Duration
.	O

Medical	O
History	O
.	O

His	O
medical	O
history	O
included	O
blunt	B-Detailed_description
chest	B-Biological_structure
trauma	B-Disease_disorder
,	O
the	O
result	O
of	O
an	O
accidental	B-Activity
fall	I-Activity
from	O
scaffolding	O
15	O
months	O
earlier	O
.	O

He	O
had	O
fallen	O
approximately	O
8	O
feet	O
and	O
had	O
landed	O
on	O
the	O
right	O
side	O
of	O
his	O
back	O
and	O
on	O
his	O
right	O
shoulder	O
.	O

The	O
patient	O
had	O
sustained	O
bilateral	B-Detailed_description
pneumothorax	B-Sign_symptom
,	O
right	B-Biological_structure
iliopsoas	I-Biological_structure
muscle	I-Biological_structure
hematoma	B-Sign_symptom
,	O
multiple	B-Detailed_description
right	B-Biological_structure
costal	I-Biological_structure
fractures	B-Sign_symptom
,	O
fracture	B-Sign_symptom
of	O
the	O
L3	B-Biological_structure
vertebral	I-Biological_structure
body	I-Biological_structure
and	O
the	O
transverse	B-Biological_structure
process	I-Biological_structure
,	O
and	O
displaced	B-Detailed_description
fractures	B-Sign_symptom
of	O
the	O
right	B-Biological_structure
clavicle	I-Biological_structure
.	O

That	O
hospitalization	O
had	O
lasted	O
40	B-Duration
days	I-Duration
,	O
during	O
which	O
time	O
the	O
clinicians	O
had	O
not	O
detected	O
any	O
murmur	B-Sign_symptom
or	O
requested	O
a	O
cardiac	B-Diagnostic_procedure
evaluation	I-Diagnostic_procedure
.	O

The	O
patient	O
returned	O
to	O
normal	B-Activity
activities	I-Activity
4	O
weeks	O
after	O
discharge	O
from	O
the	O
hospital	B-Nonbiological_location
and	O
remained	O
asymptomatic	B-Sign_symptom
for	O
one	B-Duration
year	I-Duration
.	O

Upon	O
his	O
arrival	O
at	O
our	O
department	B-Nonbiological_location
,	O
auscultation	B-Diagnostic_procedure
revealed	O
bibasilar	B-Detailed_description
rales	B-Sign_symptom
and	O
a	O
pansystolic	B-Detailed_description
murmur	B-Sign_symptom
.	O

Chest	B-Biological_structure
radiography	B-Diagnostic_procedure
showed	O
mild	B-Severity
lung	B-Biological_structure
congestion	B-Sign_symptom
;	O
and	O
transthoracic	B-Biological_structure
echocardiography	B-Diagnostic_procedure
,	O
limited	B-Detailed_description
by	I-Detailed_description
suboptimal	I-Detailed_description
acoustic	I-Detailed_description
windows	I-Detailed_description
,	O
revealed	O
severe	B-Severity
,	O
eccentric	B-Detailed_description
mitral	B-Sign_symptom
regurgitation	I-Sign_symptom
.	O

The	O
valvular	B-Biological_structure
and	O
subvalvular	B-Biological_structure
apparatus	I-Biological_structure
appeared	O
to	O
be	O
structurally	B-Sign_symptom
normal	I-Sign_symptom
,	O
and	O
the	O
left	B-Biological_structure
atrium	I-Biological_structure
was	O
only	O
mildly	B-Severity
dilated	B-Sign_symptom
.	O

The	O
patient	O
was	O
treated	O
with	O
intravenous	O
diuretics	B-Medication
until	O
the	O
signs	B-Sign_symptom
and	I-Sign_symptom
symptoms	I-Sign_symptom
of	I-Sign_symptom
congestion	I-Sign_symptom
were	O
relieved	O
.	O

Coronary	B-Biological_structure
angiography	B-Diagnostic_procedure
revealed	O
an	O
absence	O
of	O
substantial	O
coronary	B-Disease_disorder
disease	I-Disease_disorder
.	O

We	O
therefore	O
planned	O
an	O
elective	O
surgical	O
procedure	O
for	O
mitral	B-Therapeutic_procedure
valve	I-Therapeutic_procedure
repair	I-Therapeutic_procedure
.	O

Surgical	O
Procedure	O
.	O

During	O
intraoperative	B-Detailed_description
transesophageal	B-Diagnostic_procedure
echocardiography	I-Diagnostic_procedure
(	O
TEE	B-Diagnostic_procedure
)	O
,	O
we	O
observed	O
both	O
a	O
trivial	B-Severity
central	B-Detailed_description
mitral	B-Sign_symptom
regurgitant	I-Sign_symptom
jet	I-Sign_symptom
and	O
a	O
severe	B-Severity
perivalvular	B-Sign_symptom
regurgitant	I-Sign_symptom
jet	I-Sign_symptom
,	O
this	O
last	O
originating	O
from	O
a	O
ventriculoatrial	B-Biological_structure
fistulous	B-Sign_symptom
communication	I-Sign_symptom
behind	B-Biological_structure
the	I-Biological_structure
P1	I-Biological_structure
scallop	I-Biological_structure
(	O
Fig	O
.	O
1	O
)	O
.	O

Further	O
examination	O
confirmed	O
the	O
absence	O
of	O
structural	B-Disease_disorder
disease	I-Disease_disorder
involving	O
the	O
mitral	B-Biological_structure
leaflets	I-Biological_structure
or	O
subvalvular	B-Biological_structure
apparatus	I-Biological_structure
.	O

After	O
surgical	B-Therapeutic_procedure
exposure	I-Therapeutic_procedure
of	O
the	O
mitral	B-Biological_structure
valve	I-Biological_structure
,	O
a	O
small	B-Lab_value
tear	B-Sign_symptom
(	O
length	B-Distance
,	I-Distance
6	I-Distance
-	I-Distance
7	I-Distance
mm	I-Distance
)	O
could	O
be	O
seen	O
behind	B-Biological_structure
the	I-Biological_structure
posterior	I-Biological_structure
leaflet	I-Biological_structure
,	O
in	O
a	O
lateral	B-Detailed_description
position	I-Detailed_description
,	O
involving	O
also	O
the	O
annulus	B-Biological_structure
and	O
the	O
left	B-Biological_structure
atrial	I-Biological_structure
wall	I-Biological_structure
.	O

The	O
absence	O
of	O
leaflet	B-Biological_structure
abnormalities	B-Sign_symptom
or	O
vegetations	B-Sign_symptom
suggested	O
the	O
posttraumatic	B-Detailed_description
origin	I-Detailed_description
of	O
the	O
perivalvular	B-Sign_symptom
leak	I-Sign_symptom
.	O

Valvular	B-Therapeutic_procedure
repair	I-Therapeutic_procedure
was	O
successfully	O
achieved	O
by	O
direct	O
suture	B-Therapeutic_procedure
of	O
the	O
tear	O
with	O
three	B-Detailed_description
5	B-Detailed_description
-	I-Detailed_description
0	I-Detailed_description
Prolene	I-Detailed_description
stitches	B-Therapeutic_procedure
and	O
by	O
the	O
subsequent	O
insertion	O
of	O
a	O
30	B-Distance
-	I-Distance
mm	I-Distance
mitral	B-Therapeutic_procedure
annuloplasty	I-Therapeutic_procedure
ring	I-Therapeutic_procedure
.	O

The	O
patient	O
was	O
extubated	B-Therapeutic_procedure
the	O
next	O
day	O
and	O
his	O
postsurgical	B-Therapeutic_procedure
course	I-Therapeutic_procedure
was	O
uncomplicated	B-Lab_value
.	O

One	O
year	O
later	O
,	O
he	O
was	O
asymptomatic	B-Sign_symptom
,	O
and	O
his	O
one	O
-	O
year	O
follow	O
-	O
up	O
transthoracic	B-Biological_structure
echocardiogram	B-Diagnostic_procedure
confirmed	B-Lab_value
the	I-Lab_value
excellent	I-Lab_value
result	I-Lab_value
of	O
his	O
surgical	O
treatment	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
66	B-Age
year	I-Age
old	I-Age
patient	O
with	O
a	O
history	O
of	O
UC	O
treated	O
by	O
mesalazine	B-Medication
since	B-Duration
5	I-Duration
years	I-Duration
consulted	O
in	O
July	O
2012	O
for	O
a	O
painful	B-Detailed_description
erythematous	B-Detailed_description
swelling	B-Sign_symptom
of	O
the	O
back	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
hand	I-Biological_structure
.	O

The	O
bacteriological	B-Diagnostic_procedure
samples	I-Diagnostic_procedure
were	O
negative	B-Lab_value
,	O
the	O
lesion	O
was	O
considered	O
as	O
an	O
abscesses	B-Sign_symptom
and	O
the	O
patient	O
was	O
treated	O
with	O
antibiotics	B-Medication
and	O
local	B-Medication
antiseptics	I-Medication
without	O
improvement	B-Sign_symptom
.	O

The	O
evolution	O
was	O
characterized	O
by	O
the	O
appearance	O
of	O
an	O
erythematous	B-Detailed_description
vesiculobullous	B-Detailed_description
centrifugal	B-Sign_symptom
expansion	I-Sign_symptom
taking	O
the	O
whole	B-Biological_structure
back	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
hand	I-Biological_structure
treated	O
several	B-Frequency
times	I-Frequency
by	O
various	B-Medication
antibiotics	I-Medication
unsuccessfully	O
.	O

Biopsy	B-Diagnostic_procedure
of	O
this	O
lesion	O
was	O
initially	O
not	B-Lab_value
specific	I-Lab_value
.	O

In	O
October	O
2012	O
,	O
the	O
patient	O
was	O
hospitalized	O
for	O
fever	B-Sign_symptom
and	O
polyarthralgia	B-Sign_symptom
in	O
the	O
context	O
of	O
impaired	B-Sign_symptom
general	I-Sign_symptom
condition	I-Sign_symptom
.	O

He	O
had	O
a	O
quiescent	B-Detailed_description
UC	B-Disease_disorder
disease	I-Disease_disorder
.	O

The	O
skin	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
found	O
an	O
erythematous	B-Detailed_description
plaque	B-Sign_symptom
of	O
10	B-Distance
cm	I-Distance
of	O
diameter	O
,	O
with	O
a	O
raised	B-Detailed_description
border	I-Detailed_description
and	O
vesicules	B-Detailed_description
,	O
taking	O
the	O
back	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
hand	I-Biological_structure
and	O
wrist	B-Biological_structure
(	O
Figure	O
1	O
)	O
.	O

There	O
was	O
also	O
an	O
infiltrated	B-Detailed_description
erythematous	B-Detailed_description
plaque	B-Sign_symptom
on	O
the	O
right	B-Biological_structure
leg	I-Biological_structure
(	O
Figure	O
2	O
)	O
and	O
another	O
topped	B-Detailed_description
with	I-Detailed_description
a	I-Detailed_description
large	I-Detailed_description
pustule	I-Detailed_description
at	O
the	O
left	B-Biological_structure
ankle	I-Biological_structure
(	O
Figure	O
3	O
)	O
.	O

In	O
biology	O
,	O
there	O
was	O
a	O
biological	B-Disease_disorder
inflammatory	I-Disease_disorder
syndrome	I-Disease_disorder
and	O
high	B-Severity
leukocytosis	B-Sign_symptom
with	B-Detailed_description
neutrophils	I-Detailed_description
.	O

Hepatic	B-Diagnostic_procedure
and	O
renal	B-Diagnostic_procedure
functions	I-Diagnostic_procedure
were	O
normal	B-Lab_value
.	O

Skin	B-Diagnostic_procedure
biopsy	I-Diagnostic_procedure
showed	O
at	O
the	O
edge	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
back	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
closet	I-Biological_structure
right	I-Biological_structure
hand	I-Biological_structure
ulcerated	B-Sign_symptom
epidermis	I-Sign_symptom
and	O
the	O
dermis	B-Detailed_description
infiltrate	I-Detailed_description
rich	I-Detailed_description
in	I-Detailed_description
neutrophils	I-Detailed_description
with	O
leukocytoclastic	B-Detailed_description
vasculitis	B-Sign_symptom
finding	O
a	O
PG	B-Disease_disorder
(	O
Figure	O
4	O
)	O
.	O

Other	B-Diagnostic_procedure
biopsies	I-Diagnostic_procedure
taken	O
at	O
infiltrated	B-Detailed_description
erythematous	B-Detailed_description
plaques	B-Sign_symptom
of	O
the	O
ankle	B-Biological_structure
showed	O
a	O
normal	B-Lab_value
appearance	B-Diagnostic_procedure
of	I-Diagnostic_procedure
skin	I-Diagnostic_procedure
,	O
edema	B-Sign_symptom
of	O
the	O
superficial	B-Biological_structure
dermis	I-Biological_structure
based	O
on	O
an	O
infiltrate	B-Detailed_description
rich	I-Detailed_description
in	I-Detailed_description
neutrophils	I-Detailed_description
without	O
vasculitis	B-Sign_symptom
confirming	O
the	O
diagnosis	O
of	O
SS	B-Disease_disorder
(	O
Figure	O
5	O
)	O
.	O

Corticosteroid	B-Medication
treatment	O
was	O
then	O
started	O
with	O
prednisolone	B-Medication
at	O
a	O
dose	O
of	O
1	B-Dosage
mg	I-Dosage
/	I-Dosage
Kg	I-Dosage
/	I-Dosage
j	I-Dosage
.	O

The	O
evolution	O
was	O
marked	O
since	O
day	O
7	O
of	O
treatment	O
by	O
the	O
desinfiltration	B-Sign_symptom
of	I-Sign_symptom
the	I-Sign_symptom
plaques	I-Sign_symptom
(	O
Figure	O
6	O
)	O
,	O
the	O
recovery	B-Sign_symptom
of	I-Sign_symptom
the	I-Sign_symptom
general	I-Sign_symptom
condition	I-Sign_symptom
and	O
disappearance	O
of	O
biological	B-Disease_disorder
inflammatory	I-Disease_disorder
syndrome	I-Disease_disorder
.	O

-DOCSTART- -X- -X- -X- O

A	O
53	B-Age
year	I-Age
old	I-Age
female	O
without	O
significant	O
past	O
medical	O
history	O
developed	O
severe	B-Severity
viral	B-Detailed_description
pneumonia	B-Disease_disorder
,	O
with	O
rapid	B-Detailed_description
,	O
progressive	B-Detailed_description
deterioration	B-Lab_value
in	O
her	O
respiratory	B-Diagnostic_procedure
status	I-Diagnostic_procedure
.	O

She	O
developed	O
ARDS	B-Disease_disorder
and	O
mechanical	B-Therapeutic_procedure
ventilatory	I-Therapeutic_procedure
management	I-Therapeutic_procedure
using	O
ARDS	B-Detailed_description
protocol	I-Detailed_description
were	O
unable	B-Lab_value
to	I-Lab_value
maintain	I-Lab_value
adequate	I-Lab_value
oxygenation	B-Diagnostic_procedure
.	O

As	O
a	O
result	O
,	O
bedside	B-Detailed_description
VV	B-Detailed_description
-	O
ECMO	B-Therapeutic_procedure
was	O
planned	O
.	O

Transesophageal	B-Diagnostic_procedure
echocardiography	I-Diagnostic_procedure
(	O
TEE	B-Diagnostic_procedure
)	O
was	O
performed	O
to	O
visualize	O
proper	O
positioning	B-Therapeutic_procedure
of	I-Therapeutic_procedure
the	I-Therapeutic_procedure
guidewire	I-Therapeutic_procedure
and	O
cannula	B-Therapeutic_procedure
.	O

Using	O
the	O
Seldinger	B-Detailed_description
technique	I-Detailed_description
,	O
the	O
right	B-Biological_structure
internal	I-Biological_structure
jugular	I-Biological_structure
vein	I-Biological_structure
was	O
accessed	O
and	O
a	O
guide	O
wire	O
was	O
placed	O
.	O

Placement	O
of	O
the	O
guidewire	O
into	O
the	O
IVC	O
proved	O
difficult	O
due	O
to	O
repeated	O
migration	B-Detailed_description
of	I-Detailed_description
the	I-Detailed_description
guidewire	I-Detailed_description
into	O
the	O
right	B-Biological_structure
ventricle	I-Biological_structure
.	O

After	O
multiple	O
attempts	O
,	O
the	O
guidewire	O
was	O
visualized	O
to	O
course	O
properly	O
from	O
the	O
SVC	O
to	O
the	O
IVC	O
.	O

After	O
a	O
bolus	B-Detailed_description
dose	O
of	O
5000	B-Dosage
units	I-Dosage
of	O
intravenous	O
heparin	B-Medication
was	O
given	O
,	O
the	O
right	B-Biological_structure
internal	I-Biological_structure
jugular	I-Biological_structure
venous	I-Biological_structure
access	O
site	O
was	O
dilated	B-Therapeutic_procedure
.	O

Just	O
as	O
the	O
final	O
dilatation	O
was	O
completed	O
and	O
upon	O
dilator	B-Therapeutic_procedure
exchange	I-Therapeutic_procedure
with	O
simultaneous	O
advancement	O
of	O
the	O
23	B-Detailed_description
French	I-Detailed_description
Avalon	I-Detailed_description
cannula	O
,	O
TEE	B-Diagnostic_procedure
lost	B-Lab_value
visualization	I-Lab_value
of	I-Lab_value
the	I-Lab_value
guidewire	I-Lab_value
.	O

Multiple	B-Detailed_description
premature	B-Sign_symptom
ventricular	I-Sign_symptom
beats	I-Sign_symptom
were	O
noted	O
and	O
immediately	O
,	O
a	O
new	O
,	O
rapidly	B-Detailed_description
enlarging	I-Detailed_description
pericardial	B-Disease_disorder
effusion	I-Disease_disorder
was	O
detected	O
(	O
Figure	O
(	O
Figure2	O
)	O
.	O
2	O
)	O
.	O

Emergent	O
preparations	O
were	O
made	O
for	O
bedside	O
surgical	B-Therapeutic_procedure
decompression	I-Therapeutic_procedure
of	O
the	O
pericardial	B-Biological_structure
space	I-Biological_structure
.	O

Quickly	O
the	O
patient	O
lost	B-Lab_value
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
from	O
acute	B-Detailed_description
cardiac	B-Disease_disorder
tamponade	I-Disease_disorder
.	O

The	O
Avalon	B-Detailed_description
cannula	O
was	O
immediately	O
clamped	B-Detailed_description
at	I-Detailed_description
the	I-Detailed_description
end	I-Detailed_description
but	I-Detailed_description
not	I-Detailed_description
removed	I-Detailed_description
.	O

A	O
emergent	O
subxiphoid	B-Biological_structure
pericardial	B-Therapeutic_procedure
window	I-Therapeutic_procedure
was	O
performed	O
,	O
resulting	O
in	O
drainage	B-Sign_symptom
of	O
venous	B-Biological_structure
blood	I-Biological_structure
and	O
restoration	B-Lab_value
of	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
.	O

Transfusion	B-Therapeutic_procedure
was	O
initiated	O
and	O
the	O
patient	O
was	O
emergently	O
transported	O
to	O
the	O
operating	B-Nonbiological_location
room	I-Nonbiological_location
for	O
surgical	B-Diagnostic_procedure
exploration	I-Diagnostic_procedure
.	O

The	O
Avalon	B-Detailed_description
cannula	O
was	O
found	O
to	O
have	O
perforated	B-Disease_disorder
the	O
apex	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
ventricle	I-Biological_structure
.	O

The	O
injury	O
was	O
repaired	B-Therapeutic_procedure
primarily	O
and	O
the	O
Avalon	B-Detailed_description
cannula	O
was	O
repositioned	O
toward	O
the	O
IVC	B-Biological_structure
again	O
by	O
TEE	B-Diagnostic_procedure
with	O
additional	B-Detailed_description
direct	I-Detailed_description
manipulation	I-Detailed_description
.	O

VV	B-Detailed_description
-	O
ECMO	B-Therapeutic_procedure
was	O
initiated	O
and	O
the	O
oxygenation	B-Diagnostic_procedure
improved	B-Lab_value
.	O

Due	O
to	O
excessive	O
coagulopathies	B-Disease_disorder
,	O
the	O
sternum	B-Biological_structure
was	O
left	B-Therapeutic_procedure
open	I-Therapeutic_procedure
but	O
was	O
closed	B-Therapeutic_procedure
on	O
postoperative	O
day	O
2	O
.	O

From	O
that	O
point	O
,	O
she	O
remained	O
free	O
from	O
any	O
cardiac	B-Biological_structure
or	O
infectious	B-Detailed_description
complications	B-Sign_symptom
and	O
her	O
pulmonary	B-Diagnostic_procedure
condition	I-Diagnostic_procedure
slowly	B-Lab_value
improved	I-Lab_value
.	O

She	O
was	O
successfully	O
weaned	O
from	O
VV	B-Detailed_description
-	O
ECMO	B-Therapeutic_procedure
on	O
postoperative	O
day	O
9	O
and	O
was	O
discharged	O
home	B-Nonbiological_location
on	O
postoperative	O
day	O
24	O
without	O
the	O
need	O
for	O
home	B-Therapeutic_procedure
oxygen	I-Therapeutic_procedure
.	O

She	O
regained	O
full	B-Lab_value
physical	B-Diagnostic_procedure
functions	I-Diagnostic_procedure
at	O
home	O
and	O
recovered	O
normal	B-Lab_value
pulmonary	B-Diagnostic_procedure
function	I-Diagnostic_procedure
by	O
3	O
months	O
following	O
discharge	O
from	O
the	O
hospital	B-Nonbiological_location
.	O

-DOCSTART- -X- -X- -X- O

A	O
46	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
Caucasian	O
woman	O
with	O
type	O
2	O
diabetes	O
mellitus	O
and	O
bipolar	O
disorder	O
presented	O
to	O
our	O
emergency	B-Nonbiological_location
department	I-Nonbiological_location
with	O
vague	B-Detailed_description
abdominal	B-Sign_symptom
symptoms	I-Sign_symptom
and	O
vomiting	B-Sign_symptom
.	O

Her	O
pertinent	O
history	O
includes	O
left	O
below	O
knee	O
amputation	O
and	O
right	O
toes	O
amputation	O
for	O
complications	O
secondary	O
to	O
diabetic	O
neuropathy	O
.	O

At	O
the	O
time	O
of	O
admission	O
,	O
she	O
was	O
undergoing	O
care	O
for	O
an	O
infected	B-Detailed_description
diabetic	B-Detailed_description
ulcer	B-Sign_symptom
of	O
her	O
right	B-Biological_structure
foot	I-Biological_structure
.	O

Of	O
note	O
,	O
she	O
did	O
not	O
have	O
a	O
history	O
of	O
CAPD	B-Disease_disorder
or	O
a	O
history	O
of	O
renal	B-Disease_disorder
disease	I-Disease_disorder
:	O
creatinine	B-Diagnostic_procedure
1	B-Lab_value
.	I-Lab_value
23	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
blood	B-Diagnostic_procedure
urea	I-Diagnostic_procedure
nitrogen	I-Diagnostic_procedure
(	B-Diagnostic_procedure
BUN	I-Diagnostic_procedure
)	I-Diagnostic_procedure
16	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
.	O

Her	O
blood	B-Diagnostic_procedure
glucose	I-Diagnostic_procedure
levels	I-Diagnostic_procedure
were	O
poorly	B-Lab_value
controlled	I-Lab_value
via	O
subcutaneous	O
insulin	B-Medication
injection	O
;	O
she	O
reported	O
a	O
range	B-Lab_value
of	I-Lab_value
400	I-Lab_value
to	I-Lab_value
500	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
at	I-Lab_value
home	I-Lab_value
(	O
due	O
to	O
poor	O
drug	O
compliance	O
)	O
.	O

Her	O
blood	B-Diagnostic_procedure
glucose	I-Diagnostic_procedure
levels	I-Diagnostic_procedure
were	O
decreased	O
to	O
a	O
range	O
of	O
175	B-Lab_value
to	I-Lab_value
378	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
after	O
implementation	O
of	O
a	O
stricter	B-Detailed_description
insulin	B-Medication
regimen	B-Detailed_description
upon	O
admission	O
.	O

A	O
non	B-Detailed_description
-	I-Detailed_description
contrast	I-Detailed_description
CT	B-Diagnostic_procedure
scan	I-Diagnostic_procedure
showed	O
confluent	B-Detailed_description
,	O
bilobar	B-Biological_structure
geographic	O
regions	O
of	O
hypoattenuation	B-Sign_symptom
in	O
a	O
subcapsular	B-Detailed_description
distribution	I-Detailed_description
throughout	O
her	O
liver	B-Biological_structure
(	O
Fig	O
.	O
1	O
)	O
.	O

A	O
MRI	B-Diagnostic_procedure
liver	B-Biological_structure
protocol	O
was	O
performed	O
for	O
further	O
evaluation	O
of	O
these	O
indeterminate	O
findings	O
to	O
assess	O
for	O
possible	O
vascular	O
etiology	O
as	O
areas	O
of	O
infarction	O
could	O
also	O
be	O
possible	O
in	O
this	O
patient	O
.	O

In	B-Detailed_description
-	I-Detailed_description
phase	I-Detailed_description
gradient	B-Diagnostic_procedure
echo	I-Diagnostic_procedure
images	O
demonstrated	O
hyperintense	B-Detailed_description
foci	B-Sign_symptom
in	O
her	O
liver	B-Biological_structure
in	O
a	O
distribution	O
corresponding	O
to	O
the	O
hypoattenuating	O
regions	O
seen	O
on	O
CT	O
.	O

On	O
the	O
opposed	B-Diagnostic_procedure
-	I-Diagnostic_procedure
phase	I-Diagnostic_procedure
sequence	I-Diagnostic_procedure
,	O
there	O
was	O
loss	B-Lab_value
in	I-Lab_value
signal	I-Lab_value
within	O
these	O
areas	O
indicating	O
the	O
presence	B-Sign_symptom
of	I-Sign_symptom
intracellular	I-Sign_symptom
fat	I-Sign_symptom
and	I-Sign_symptom
water	I-Sign_symptom
(	O
Fig	O
.	O
2	O
)	O
.	O

In	O
addition	O
,	O
these	O
areas	O
were	O
hypointense	O
to	O
the	O
remaining	O
hepatic	B-Biological_structure
parenchyma	I-Biological_structure
on	O
the	O
fat	O
suppression	O
MR	O
sequences	O
,	O
confirming	O
presence	B-Sign_symptom
of	I-Sign_symptom
fat	I-Sign_symptom
and	O
thus	O
establishing	O
a	O
diagnosis	O
of	O
SHS	B-Disease_disorder
.	O

Furthermore	O
,	O
a	O
follow	O
-	O
up	O
CT	B-Diagnostic_procedure
of	O
her	O
abdomen	B-Biological_structure
and	O
pelvis	B-Biological_structure
was	O
performed	O
3	O
months	O
later	O
,	O
which	O
showed	O
near	B-Sign_symptom
complete	I-Sign_symptom
resolution	I-Sign_symptom
of	O
these	O
findings	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Of	O
note	O
,	O
stricter	O
glucose	B-Therapeutic_procedure
control	I-Therapeutic_procedure
had	O
decreased	O
her	O
average	O
blood	B-Diagnostic_procedure
glucose	I-Diagnostic_procedure
level	I-Diagnostic_procedure
to	O
below	B-Lab_value
200	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
.	O

